{"content":"<li class=\"n-box-item date-title\" data-end=\"1516424399\" data-start=\"1516338000\" data-txt=\"Monday, December 23, 2019\">Friday, January 19, 2018</li><li class=\"n-box-item sa-box-item\" data-id=\"3324000\" data-ts=\"1516402996\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FOSL\" target=\"_blank\">FOSL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324000-fossil-group-jumps-on-speculation-of-private-buyout\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fossil Group jumps on speculation of private buyout</a></h4><ul>   <li>Fossil Group (<a href=\"http://seekingalpha.com/symbol/FOSL\" target=\"_blank\">FOSL</a> <font color='green'>+10.1%</font>) pulled a double-digit gain today, cresting the $10 mark for the first time since August on speculation of a takeover.</li>    <li>A StreetAccount report said private-equity firm Thoma Bravo could be interested in acquiring the watchmaker for about $15.75/share.</li>    <li>That price would mark a 73% premium over yesterday's close, and is 57% upside from today's closing price.</li>    <li>Fossil shares have <font color='red'>lost 60%</font> of value over the past 12 months, from where it was hovering around the $25 mark.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3324000\" data-linked=\"Fossil Group jumps on speculation of private buyout\" data-tweet=\"$FOSL - Fossil Group jumps on speculation of private buyout https://seekingalpha.com/news/3324000-fossil-group-jumps-on-speculation-of-private-buyout?source=tweet\" data-url=\"https://seekingalpha.com/news/3324000-fossil-group-jumps-on-speculation-of-private-buyout\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323997\" data-ts=\"1516401656\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SANM\" target=\"_blank\">SANM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323997-sanmina-sinks-on-earnings-revenue-warning\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sanmina sinks on earnings, revenue warning</a></h4><ul>     <li>Sanmina (NASDAQ:<a href='https://seekingalpha.com/symbol/SANM' title='Sanmina Corp'>SANM</a>) <font color='red'>-18.2%</font> after-hours following <a href=\"https://seekingalpha.com/pr/17051562-sanmina-announces-preliminary-first-quarter-fiscal-2018-results\" target=\"_blank\">downbeat guidance</a> for its December and March quarters, driven by slower than expected new program ramps and an unfavorable program mix.</li>     <li>SANM now sees FQ1 (Dec.) adjusted EPS of $0.48 on revenue of $1.74B, compared with its previous guidance of $0.68-$0.74 EPS and revenue of $1.75B-$1.8B; analyst consensus for the quarter was $0.71 EPS earnings on sales of $1.77B.</li><li>For FQ2 (Mar.), the company expects EPS of $0.40-$0.50 on revenues of  $1.6B-$1.7B, below analysts consensus of $0.70 EPS and $1.73B in sales.</li><li>SANM says it is right-sizing its fixed cost structure and expects H2 2018 results will be stronger than H1.</li></ul><div class=\"tiny-share-widget\" data-id=\"3323997\" data-linked=\"Sanmina sinks on earnings, revenue warning\" data-tweet=\"$SANM - Sanmina sinks on earnings, revenue warning https://seekingalpha.com/news/3323997-sanmina-sinks-on-earnings-revenue-warning?source=tweet\" data-url=\"https://seekingalpha.com/news/3323997-sanmina-sinks-on-earnings-revenue-warning\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:40 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>25&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323996\" data-ts=\"1516401595\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AVT\" target=\"_blank\">AVT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323996-avnet-marks-banner-day-longbow-raises-to-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Avnet marks banner day as Longbow raises to Buy</a></h4><ul>   <li>Avnet (NASDAQ:<a href='https://seekingalpha.com/symbol/AVT' title='Avnet Inc'>AVT</a>) saw its best gain in over a year, <font color='green'>up 4.8%</font> today, after a Longbow upgrade that looks to a healthy environment for demand and favorable pricing.</li>    <li>The firm raised its rating to Buy from Neutral.</li>    <li>The company's trailing Arrow Electronics (NYSE:<a href='https://seekingalpha.com/symbol/ARW' title='Arrow Electronics Inc'>ARW</a>) in new customer development, Longbow notes, but it's still making progress. <a href='https://seekingalpha.com/symbol/ARW' title='Arrow Electronics Inc'>ARW</a> <font color='green'>gained 3.3%</font> today.</li>    <li>The firm cited expectations for mid-single-digit to double-digit growth for Avnet in calendar 2018.</li>    <li>Avnet shares had risen as much as 5.9% today.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3323996\" data-linked=\"Avnet marks banner day as Longbow raises to Buy\" data-tweet=\"$AVT $AVT $ARW - Avnet marks banner day as Longbow raises to Buy https://seekingalpha.com/news/3323996-avnet-marks-banner-day-longbow-raises-to-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3323996-avnet-marks-banner-day-longbow-raises-to-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:39 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323993\" data-ts=\"1516401361\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323993-after-hours-gainers-losers-1-19-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers (1/19/2018)</a></h4><ul>     <li><b>Top gainers:</b> <a href='https://seekingalpha.com/symbol/HIVE' title='Aerohive Networks, Inc.'>HIVE</a> <font color='green'>+3.1%</font>. <a href='https://seekingalpha.com/symbol/BG' title='Bunge Limited'>BG</a> <font color='green'>+1.5%</font>. <a href='https://seekingalpha.com/symbol/CRTO' title='Criteo S.A.'>CRTO</a> <font color='green'>+1.9%</font>. <a href='https://seekingalpha.com/symbol/OKTA' title='Okta, Inc.'>OKTA</a> <font color='green'>+1.8%</font>.</li><li><b>Top losers:</b> <a href='https://seekingalpha.com/symbol/SANM' title='Sanmina Corp'>SANM</a> <font color='red'>-18.1%</font>. <a href='https://seekingalpha.com/symbol/FTR' title='Frontier Communications Corporation'>FTR</a> <font color='red'>-2.6%</font>. <a href='https://seekingalpha.com/symbol/ATRO' title='Astronics Corporation'>ATRO</a> <font color='red'>-2.1%</font>. <a href='https://seekingalpha.com/symbol/FRAC' title='Keane Group'>FRAC</a> <font color='red'>-1.7%</font>. <a href='https://seekingalpha.com/symbol/GIII' title='G-III Apparel Group, LTD.'>GIII</a> <font color='red'>-1.6%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3323993\" data-linked=\"After Hours Gainers / Losers (1/19/2018)\" data-tweet=\"$HIVE $BG $CRTO - After Hours Gainers / Losers (1/19/2018) https://seekingalpha.com/news/3323993-after-hours-gainers-losers-1-19-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3323993-after-hours-gainers-losers-1-19-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323984\" data-ts=\"1516398390\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323984-weekly-etf-gainers-losers-1-19-18\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Weekly ETF Gainers / Losers (1/19/18)</a></h4><ul>     <li><b>Top gainers:</b> <a href='https://seekingalpha.com/symbol/FXI' title='iShares China Large-Cap ETF'>FXI</a> <font color='green'>+4.3%</font>. <a href='https://seekingalpha.com/symbol/VXX' title='iPath S&P 500 VIX Short-Term Futures ETN'>VXX</a> <font color='green'>+3.8%</font>. <a href='https://seekingalpha.com/symbol/ILF' title='iShares Latin America 40 ETF'>ILF</a> <font color='green'>+3.1%</font>. <a href='https://seekingalpha.com/symbol/EWZ' title='iShares MSCI Brazil Capped ETF'>EWZ</a> <font color='green'>+2.9%</font>. <a href='https://seekingalpha.com/symbol/DEM' title='WisdomTree Emerging Markets High Dividend ETF'>DEM</a> <font color='green'>+2.6%</font>.</li><li><b>Top losers:</b> <a href='https://seekingalpha.com/symbol/REMX' title='VanEck Vectors Rare Earth/Strategic Metals ETF'>REMX</a> <font color='red'>-5.5%</font>. <a href='https://seekingalpha.com/symbol/URA' title='Global X Uranium ETF'>URA</a> <font color='red'>-4.8%</font>. <a href='https://seekingalpha.com/symbol/FCG' title='First Trust Natural Gas ETF'>FCG</a> <font color='red'>-2.9%</font>. <a href='https://seekingalpha.com/symbol/TAN' title='Guggenheim Solar ETF'>TAN</a> <font color='red'>-2.4%</font>. <a href='https://seekingalpha.com/symbol/PSLV' title='Sprott Physical Silver Trust'>PSLV</a> <font color='red'>-1.7%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3323984\" data-linked=\"Weekly ETF Gainers / Losers (1/19/18)\" data-tweet=\"$FXI $VXX $ILF - Weekly ETF Gainers / Losers (1/19/18) https://seekingalpha.com/news/3323984-weekly-etf-gainers-losers-1-19-18?source=tweet\" data-url=\"https://seekingalpha.com/news/3323984-weekly-etf-gainers-losers-1-19-18\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:46 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323987\" data-ts=\"1516398345\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HGT-OLD\" target=\"_blank\">HGT-OLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323987-hugoton-royalty-trust-skips-jan-distribution-updates-on-xto-settlement-amount\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hugoton Royalty Trust skips Jan. distribution &amp; updates on XTO settlement amount</a></h4><ul>     <li>Southwest Bank, as Trustee of the Hugoton Royalty Trust (NYSE:<a href='https://seekingalpha.com/symbol/HGT-OLD' title='Hugoton Royalty Trust'>HGT-OLD</a>) today declared there would not be a cash distribution to the holders of its units of beneficial interest for the month of Jan. 2018.</li>     <li>XTO Energy informed the Trustee on Jan. 17, 2018, that it believes that the portion of the settlement that relates to the Trust is as much as $20M.</li>     <li>The settlement requires final approval by a judge, which is expected to occur in late Q118.</li><li>Shares&nbsp;<font color='red'>-38% AH</font></li><li><a href=\"https://seekingalpha.com/pr/17051561-hugoton-royalty-trust-declares-january-cash-distribution-gives-notice-tentative-xto\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3323987\" data-linked=\"Hugoton Royalty Trust skips Jan. distribution &amp; updates on XTO settlement amount\" data-tweet=\"$HGT-OLD - Hugoton Royalty Trust skips Jan. distribution &amp; updates on XTO settlement amount https://seekingalpha.com/news/3323987-hugoton-royalty-trust-skips-jan-distribution-updates-on-xto-settlement-amount?source=tweet\" data-url=\"https://seekingalpha.com/news/3323987-hugoton-royalty-trust-skips-jan-distribution-updates-on-xto-settlement-amount\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:45 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323965\" data-ts=\"1516395118\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GMLP\" target=\"_blank\">GMLP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323965-golar-lng-partners-secures-long-term-fsru-contract\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Golar LNG Partners secures long-term FSRU contract</a></h4><ul>     <li>Golar LNG&nbsp;Partners (<a href='https://seekingalpha.com/symbol/GMLP' title='Golar LNG Partners LP'>GMLP</a> <font color='green'>+2.1%</font>) is higher after <a href=\"https://seekingalpha.com/pr/17051170-golar-lng-partners-l-p-secures-new-long-term-fsru-contract\" target=\"_blank\">signing a 15-year contract</a> with an unnamed energy and logistics for a floating storage and regasification unit in the Atlantic Basin beginning in Q4 2018.</li>     <li>GMLP says expects the vessel to generate $18M-$22M in operating income each year before depreciation and amortization, although the charter rate will vary based on demand for regasification throughput.</li>     <li>GMLP says the new contract \"reflects the growing interest in smaller, cost competitive FSRUs that  can facilitate the opening of niche markets previously considered  uneconomic for LNG.\"</li><li><a href='https://seekingalpha.com/symbol/GLNG' title='Golar LNG Limited'>GLNG</a> <font color='green'>+1.5%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3323965\" data-linked=\"Golar LNG Partners secures long-term FSRU contract\" data-tweet=\"$GMLP $GMLP $GLNG - Golar LNG Partners secures long-term FSRU contract https://seekingalpha.com/news/3323965-golar-lng-partners-secures-long-term-fsru-contract?source=tweet\" data-url=\"https://seekingalpha.com/news/3323965-golar-lng-partners-secures-long-term-fsru-contract\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:51 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323962\" data-ts=\"1516394670\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CMG\" target=\"_blank\">CMG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323962-chipotleplus-2-raymond-james-upgrades-cowen-still-sour-view\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Chipotle +2% as Raymond James upgrades, but Cowen still has sour view</a></h4><ul>     <li>Chipotle Mexican Grill (<a href='https://seekingalpha.com/symbol/CMG' title='Chipotle Mexican Grill, Inc.'>CMG</a> <font color='green'>+1.9%</font>) is higher after Raymond James <a href=\"https://www.barrons.com/articles/chipotle-its-getting-betteror-not-1516392171\" target=\"_blank\">upgrades</a> shares to Market Perform from Underperform, as the firm no longer sees downside risk to 2018 estimates, citing CMG's decision for a third round of menu price increases, along with stabilizing industry trends.</li><li>Bernstein analysts reiterate their Outperform rating on CMG as part of a broader <a href=\"https://www.barrons.com/articles/bigger-is-better-when-it-comes-to-2018s-restaurant-winners-1516383712\" target=\"_blank\">upbeat view of restaurants</a>, which they think will benefit this year from lower corporate taxes and improving trends.</li><li>However, the team at Cowen reiterates its Underperform rating on the stock, saying Facebook check-ins suggest falling traffic trends toward trough levels seen at the start of the year.</li></ul><div class=\"tiny-share-widget\" data-id=\"3323962\" data-linked=\"Chipotle +2% as Raymond James upgrades, but Cowen still has sour view\" data-tweet=\"$CMG - Chipotle +2% as Raymond James upgrades, but Cowen still has sour view https://seekingalpha.com/news/3323962-chipotleplus-2-raymond-james-upgrades-cowen-still-sour-view?source=tweet\" data-url=\"https://seekingalpha.com/news/3323962-chipotleplus-2-raymond-james-upgrades-cowen-still-sour-view\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:44 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>25&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323959\" data-ts=\"1516393437\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AVEO\" target=\"_blank\">AVEO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323959-aveo-oncologys-tivozanib-shows-positive-effect-in-early-stage-liver-cancer-study-shares-ahead\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AVEO Oncology&#39;s tivozanib shows positive effect in early-stage liver cancer study; shares ahead 5%</a></h4><ul><li>AVEO Oncology (<a href='https://seekingalpha.com/symbol/AVEO' title='AVEO Pharmaceuticals, Inc.'>AVEO</a> <font color='green'>+5.4%</font>) is up on 30% higher volume in response to <a href=\"https://seekingalpha.com/pr/17051495-aveo-oncology-announces-presentation-data-phase-1b-2-study-tivozanib-patients-advanced\" target=\"_blank\">positive results</a> from the Phase 1b portion of a Phase 1b/2 clinical trial assessing lead drug FOTIVDA (tivozanib) in patients with advanced unresectable hepatocellular carcinoma &#40;HCC&#41;. The data were presented at the ASCO-GI Symposium in San Francisco.</li><li>Median progression-free survival &#40;PFS&#41; in 19 evaluable patients at week 24 was 5.5 months and 47% (n=9/19) had stable disease. The disease control rate (responders + those with stable cancer) was 63% (n=12/19), including four partial responders and eight with stable disease. Four subjects remained progression-free for over two years. Overall survival &#40;OS&#41; at month 6 and month 12 was 58% and 25%, respectively.</li><li>On the safety front, two patients experienced dose-limiting toxicities (Grade 3 mucositis and hypertension) upon receiving the 1.5 mg dose (highest) and withdrew from the study.</li><li>The 1.0 mg dose will be evaluated in the Phase 2 portion.</li><li><a href=\"http://www.aveooncology.com/our-product-candidates/tivozanib/\" target=\"_blank\">Tivozanib&nbsp;</a>is an oral, once-daily, vascular endothelial growth factor &#40;VEGF&#41; tyrosine kinase inhibitor &#40;TKI&#41;. It is designed to optimize VEGF blockade while minimizing toxic side effects.</li></ul><div class=\"tiny-share-widget\" data-id=\"3323959\" data-linked=\"AVEO Oncology&#39;s tivozanib shows positive effect in early-stage liver cancer study; shares ahead 5%\" data-tweet=\"$AVEO - AVEO Oncology&#39;s tivozanib shows positive effect in early-stage liver cancer study; shares ahead 5% https://seekingalpha.com/news/3323959-aveo-oncologys-tivozanib-shows-positive-effect-in-early-stage-liver-cancer-study-shares-ahead?source=tweet\" data-url=\"https://seekingalpha.com/news/3323959-aveo-oncologys-tivozanib-shows-positive-effect-in-early-stage-liver-cancer-study-shares-ahead\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:23 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323958\" data-ts=\"1516392770\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SMHI\" target=\"_blank\">SMHI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323958-seacor-marine-in-stalking-horse-bid-for-jv-montco-offshore\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Seacor Marine in stalking horse bid for JV with Montco Offshore</a></h4><ul>     <li>Seacor Marine (<a href='https://seekingalpha.com/symbol/SMHI' title='SEACOR Marine Holdings Inc'>SMHI</a> <font color='green'>+5.1%</font>) is higher after confirming a <a href=\"https://seekingalpha.com/pr/17051033-seacor-marine-announces-confirmation-stalking-horse-bid-form-joint-venture-montco-offshore\" target=\"_blank\">stalking horse bid</a> to form a joint venture with Montco Offshore, which is reorganizing in U.S. bankruptcy court.</li>     <li>Seacor says the new JV would consolidate ownership and operation of 11 liftboat vessels  currently operated by a wholly-owned subsidiary, six liftboat vessels currently operated by Montco, and two liftboat vessels currently operated by an existing JV between the two companies.</li><li>Upon completion of the transactions, Seacor expects to hold at least 70% of all equity interests in the new JV.</li></ul><div class=\"tiny-share-widget\" data-id=\"3323958\" data-linked=\"Seacor Marine in stalking horse bid for JV with Montco Offshore\" data-tweet=\"$SMHI - Seacor Marine in stalking horse bid for JV with Montco Offshore https://seekingalpha.com/news/3323958-seacor-marine-in-stalking-horse-bid-for-jv-montco-offshore?source=tweet\" data-url=\"https://seekingalpha.com/news/3323958-seacor-marine-in-stalking-horse-bid-for-jv-montco-offshore\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:12 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323954\" data-ts=\"1516391831\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323954-technology-top-gainers-losers-of-2_55-pm-1-19-18\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 2.55 pm (1/19/18)</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/AIRG' title='Airgain'>AIRG</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/MIND' title='Mitcham Industries, Inc.'>MIND</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/KEM' title='KEMET Corp.'>KEM</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/OKTA' title='Okta, Inc.'>OKTA</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/GRPN' title='Groupon, Inc.'>GRPN</a> <font color='green'>+9%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/CPAH' title='CounterPath Corporation'>CPAH</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/IPHI' title='Inphi Corporation'>IPHI</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/LEDS' title='SemiLEDs Corporation'>LEDS</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/RUBI' title='The Rubicon Project, Inc.'>RUBI</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/DQ' title='DAQO New Energy Corp.'>DQ</a> <font color='red'>-6%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3323954\" data-linked=\"Technology - Top Gainers / Losers as of 2.55 pm (1/19/18)\" data-tweet=\"$AIRG $MIND $KEM - Technology - Top Gainers / Losers as of 2.55 pm (1/19/18) https://seekingalpha.com/news/3323954-technology-top-gainers-losers-of-2_55-pm-1-19-18?source=tweet\" data-url=\"https://seekingalpha.com/news/3323954-technology-top-gainers-losers-of-2_55-pm-1-19-18\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:57 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323947\" data-ts=\"1516390015\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AR\" target=\"_blank\">AR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323947-antero-resources-leads-gas-e-and-ps-lower-on-weather-meh-analyst-day\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Antero Resources leads gas E&amp;Ps lower on weather, &#39;meh&#39; analyst day</a></h4><ul>     <li>Antero Resources (<a href='https://seekingalpha.com/symbol/AR' title='Antero Resources Corporation'>AR</a> <font color='red'>-4.6%</font>) sinks nearly 5% on milder U.S. weather and after its analyst day <a href=\"https://seekingalpha.com/news/3323436-antero-resources-partnerships-give-upbeat-2018-guidance\" target=\"_blank\">earlier this week</a>, which Capital One analyst Brian Velie calls \"meh.\"</li><li>AR's management asserted that the company is now at an inflection point in its ability to generate free cash.</li>     <li>Separately, Jefferies analysts say AR&rsquo;s natural gas liquids leverage is compelling but capital efficiency remains a \"show me\" story.</li><li>The stock is today's worst performer in the S&amp;P oil and gas E&amp;P&nbsp;ETF (<a href='https://seekingalpha.com/symbol/XOP' title='SPDR S&P Oil & Gas Exploration & Production ETF'>XOP</a> <font color='red'>-0.8%</font>), behind gas-exposed Gulfport Energy (<a href='https://seekingalpha.com/symbol/GPOR' title='Gulfport Energy Corporation'>GPOR</a> <font color='red'>-3.9%</font>) and Range  Resources (<a href='https://seekingalpha.com/symbol/RRC' title='Range Resources Corporation'>RRC</a> <font color='red'>-3.6%</font>).</li>     <li>Source:&nbsp;Bloomberg First Word</li> </ul><div class=\"tiny-share-widget\" data-id=\"3323947\" data-linked=\"Antero Resources leads gas E&amp;Ps lower on weather, &#39;meh&#39; analyst day\" data-tweet=\"$AR $AR $XOP - Antero Resources leads gas E&amp;Ps lower on weather, &#39;meh&#39; analyst day https://seekingalpha.com/news/3323947-antero-resources-leads-gas-e-and-ps-lower-on-weather-meh-analyst-day?source=tweet\" data-url=\"https://seekingalpha.com/news/3323947-antero-resources-leads-gas-e-and-ps-lower-on-weather-meh-analyst-day\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:26 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>51&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323945\" data-ts=\"1516389543\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TNXP\" target=\"_blank\">TNXP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323945-tonix-pharma-up-3-on-smallpox-progress\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tonix Pharma up 3% on smallpox progress</a></h4><ul><li>Research published today&nbsp;describes the successful synthesis and characterization of a potential smallpox-preventing vaccine based on horsepox virus.</li><li>The company is developing a synthetic version of horsepox virus from cell culture (TNX-801) as a potential vaccine for smallpox in humans.</li><li>Source: <a href=\"https://seekingalpha.com/pr/17051484-tonix-pharmaceuticals-announces-publication-reporting-synthesis-construction-characterization\" target=\"_blank\">Press Release</a></li><li><a href='https://seekingalpha.com/symbol/TNXP' title='Tonix Pharmaceuticals Holding Corp.'>TNXP</a>&nbsp;<font color='green'>+3.3%</font></li></ul><div class=\"tiny-share-widget\" data-id=\"3323945\" data-linked=\"Tonix Pharma up 3% on smallpox progress\" data-tweet=\"$TNXP - Tonix Pharma up 3% on smallpox progress https://seekingalpha.com/news/3323945-tonix-pharma-up-3-on-smallpox-progress?source=tweet\" data-url=\"https://seekingalpha.com/news/3323945-tonix-pharma-up-3-on-smallpox-progress\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:19 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323944\" data-ts=\"1516389078\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FB\" target=\"_blank\">FB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323944-bloomberg-facebook-wont-bid-on-thursday-night-nfl\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bloomberg: Facebook won&#39;t bid on Thursday night NFL</a></h4><ul>   <li>After a couple of years of spending on live sports, Facebook (<a href=\"http://seekingalpha.com/symbol/FB\" target=\"_blank\">FB</a> <font color='green'>+0.9%</font>) is <a href=\"https://www.bloomberg.com/news/articles/2018-01-19/facebook-is-said-to-decide-against-thursday-night-football-bid\" target=\"_blank\">bowing out of competing</a> for Thursday night NFL games, Bloomberg reports.</li>    <li>The league is expected to decide on rights to stream the 2018 season's Thursday games by the end of February.</li>    <li>Skipping the NFL games doesn't mean the company is shying away from expensive sports rights, a source told Bloomberg; it had offered $600M for rights to an Indian cricket league but lost that bid to Fox.</li>    <li>Amazon.com (<a href=\"http://seekingalpha.com/symbol/AMZN\" target=\"_blank\">AMZN</a> <font color='green'>+0.6%</font>) won the 2017 Thursday-night rights for $50M, but hasn't indicated whether it will bid again. Meanwhile, CBS (<a href=\"http://seekingalpha.com/symbol/CBS\" target=\"_blank\">CBS</a> <font color='red'>-2.9%</font>) and NBC (<a href=\"http://seekingalpha.com/symbol/CMCSA\" target=\"_blank\">CMCSA</a> <font color='green'>+1.5%</font>), which paid a combined $450M for TV rights to Thursdays this year, are looking to pay less for the same rights in 2018.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3323944\" data-linked=\"Bloomberg: Facebook won&#39;t bid on Thursday night NFL\" data-tweet=\"$FB $FB $AMZN - Bloomberg: Facebook won&#39;t bid on Thursday night NFL https://seekingalpha.com/news/3323944-bloomberg-facebook-wont-bid-on-thursday-night-nfl?source=tweet\" data-url=\"https://seekingalpha.com/news/3323944-bloomberg-facebook-wont-bid-on-thursday-night-nfl\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:11 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>27&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323943\" data-ts=\"1516389011\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GE\" target=\"_blank\">GE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323943-ge-slides-another-3-deutsche-bank-says-may-need-to-raise-equity-capital\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GE slides another 3%; Deutsche Bank says may need to raise equity capital</a></h4><ul>     <li>General Electric (<a href='https://seekingalpha.com/symbol/GE' title='General Electric'>GE</a> <font color='red'>-3.2%</font>) shares tumble to a <a href=\"https://www.reuters.com/article/us-ge-stocks/general-electric-shares-drop-for-fifth-straight-session-idUSKBN1F82BG?il=0\" target=\"_blank\">fifth straight decline</a>, threatening to fall below $16 only a day after breaching $17 for the first time since 2011.</li>     <li>GE rebounded as much as 11% to start the new year but has now dropped more than 6%&nbsp;YTD and is the Dow's worst performing member again this year after winning the same dubious distinction in 2017.</li>     <li>The latest negative vibe comes via Deutsche Bank analyst John Inch, who says GE's current cash squeeze and growing liquidity pressure <a href=\"https://www.barrons.com/articles/ge-why-theres-still-more-pain-coming-1516382855\" target=\"_blank\">may force the company to raise equity capital</a>.</li>     <li>Inch, who has a Sell rating on GE with a $15 price target, sees plenty of risks beyond any equity capital raise, including&nbsp;additional mandated insurance reserve contributions, increasing debt and debt rating downgrades, and another dividend cut.</li></ul><div class=\"tiny-share-widget\" data-id=\"3323943\" data-linked=\"GE slides another 3%; Deutsche Bank says may need to raise equity capital\" data-tweet=\"$GE - GE slides another 3%; Deutsche Bank says may need to raise equity capital https://seekingalpha.com/news/3323943-ge-slides-another-3-deutsche-bank-says-may-need-to-raise-equity-capital?source=tweet\" data-url=\"https://seekingalpha.com/news/3323943-ge-slides-another-3-deutsche-bank-says-may-need-to-raise-equity-capital\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>190&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323942\" data-ts=\"1516388549\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMG\" target=\"_blank\">AMG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323942-affiliated-managers-gains-4-after-citi-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Affiliated Managers gains 4% after Citi upgrade</a></h4><ul><li>The big run continues as Citi's William Katz climbs on board, upgrading to Buy from Neutral. His $250 price target suggests&nbsp;<font color='green'>17% upside</font>.</li><li>Katz takes note of improved earnings quality and capital management flexibility.</li><li><a href='https://seekingalpha.com/symbol/AMG' title='Affiliated Managers Group'>AMG</a>&nbsp;<font color='green'>+3.8%</font>&nbsp;today, and&nbsp;<font color='green'>51%</font>&nbsp;Y/Y.</li></ul><div class=\"tiny-share-widget\" data-id=\"3323942\" data-linked=\"Affiliated Managers gains 4% after Citi upgrade\" data-tweet=\"$AMG - Affiliated Managers gains 4% after Citi upgrade https://seekingalpha.com/news/3323942-affiliated-managers-gains-4-after-citi-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3323942-affiliated-managers-gains-4-after-citi-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:02 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323941\" data-ts=\"1516388496\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323941-energy-materials-top-gainers-losers-of-2-00-pm-1-19-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm (1/19/2018)</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/GSV' title='Gold Standard Ventures'>GSV</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/ACH' title='Aluminum Corporation of China Ltd'>ACH</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/OSN' title='Ossen Innovation Co., Ltd.'>OSN</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/WLB' title='Westmoreland Coal Co'>WLB</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/MNGA' title='MagneGas Corporation'>MNGA</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/RCON' title='Recon Technology, Ltd.'>RCON</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/NDRO-OLD' title='Enduro Royalty Trust'>NDRO-OLD</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/BPT' title='BP Prudhoe Bay Royalty Trust'>BPT</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/IO' title='ION Geophysical Corporation'>IO</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3323941\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm (1/19/2018)\" data-tweet=\"$GSV $ACH $OSN - Energy/Materials - Top Gainers / Losers as of 2:00 pm (1/19/2018) https://seekingalpha.com/news/3323941-energy-materials-top-gainers-losers-of-2-00-pm-1-19-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3323941-energy-materials-top-gainers-losers-of-2-00-pm-1-19-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323937\" data-ts=\"1516388222\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MON\" target=\"_blank\">MON</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323937-monsanto-bayer-nearing-doj-green-light-capital-forum\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Monsanto/Bayer nearing DOJ green light - Capital Forum</a></h4><ul><li>Monsanto (NYSE:<a href='https://seekingalpha.com/symbol/MON' title='Monsanto Company'>MON</a>) and Bayer (<a href='https://seekingalpha.com/symbol/BAYRY' title='Bayer A.G. ADR'>OTCPK:BAYRY</a>) are getting closer toward a consent decree with the Justice Department, <a href=\"https://thecapitolforum.com/\" target=\"_blank\">according to the report</a>.</li><li>Monsanto has moved higher since headline crossed, now&nbsp;<font color='green'>up 1.75%</font>&nbsp;on the session.</li></ul><div class=\"tiny-share-widget\" data-id=\"3323937\" data-linked=\"Monsanto/Bayer nearing DOJ green light - Capital Forum\" data-tweet=\"$MON $MON $BAYRY - Monsanto/Bayer nearing DOJ green light - Capital Forum https://seekingalpha.com/news/3323937-monsanto-bayer-nearing-doj-green-light-capital-forum?source=tweet\" data-url=\"https://seekingalpha.com/news/3323937-monsanto-bayer-nearing-doj-green-light-capital-forum\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:57 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323936\" data-ts=\"1516387806\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAPL\" target=\"_blank\">AAPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323936-techcrunch-apple-hires-tech-team-from-business-consulting-startup\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TechCrunch: Apple hires tech team from business consulting startup</a></h4><ul><li>        Apple (NASDAQ:<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a>) has hired the tech team from Silicon Valley Data Science, a business transformation consulting startup, according to <a href=\"https://techcrunch.com/2018/01/19/apple-has-hired-tech-team-from-data-science-startup-svds/\" target=\"_blank\">TechCrunch</a>.</li><li>               Silicon Valley Data Science uses data science and engineering solutions in its consulting services.&nbsp;</li><li>               Apple reportedly hired at least 18 members of the staff (roughly half to one-third of the total) including a co-founder/CTO and the other co-founder/CEO.&nbsp;</li><li>               Apple did not acquire the company.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3323903-apple-suppliers-drop-key-analyst-lowers-iphone-x-lifetime-sales-forecast\" target=\"_blank\">Apple, suppliers drop as key analyst lowers iPhone X lifetime sales forecast</a> (Jan. 19)</li></ul><div class=\"tiny-share-widget\" data-id=\"3323936\" data-linked=\"TechCrunch: Apple hires tech team from business consulting startup\" data-tweet=\"$AAPL - TechCrunch: Apple hires tech team from business consulting startup https://seekingalpha.com/news/3323936-techcrunch-apple-hires-tech-team-from-business-consulting-startup?source=tweet\" data-url=\"https://seekingalpha.com/news/3323936-techcrunch-apple-hires-tech-team-from-business-consulting-startup\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:50 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323931\" data-ts=\"1516386599\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IBM\" target=\"_blank\">IBM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323931-analysts-comment-on-ibms-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Analysts comment on IBM&#39;s earnings</a></h4><ul><li>Analysts comment on IBM&rsquo;s (NYSE:<a href='https://seekingalpha.com/symbol/IBM' title='International Business Machines Corporation'>IBM</a>) earnings report yesterday, which beat estimates with revenue growth but included margin erosion.</li><li>Cantor Fitzgerald&rsquo;s Joseph Foresi notes that the first revenue growth in nearly six years came from strength in Systems and a hardware refresh cycle.</li><li>But Foresi says IBM needs to return to consistent growth and margin expansion before a valuation multiple expansion can happen.</li><li>Cantor rates IBM at Neutral with a $152 price target.</li><li>More action: RBC&rsquo;s Amit Daryanani questions the &ldquo;quality&rdquo; of the earnings since the non-GAAP tax rate was 6%, well below expectations, and gross margins were &ldquo;soft.&rdquo;</li><li>Daryanani does say the CY18 guidance was &ldquo;incrementally better&rdquo; and could signal stabilization ahead.</li><li>RBC rates IBM at Outperform with a $180 price target.</li><li>Source: Bloomberg First Word</li><li>IBM shares are&nbsp;<font color='red'>down 4.5%</font>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3323747-ibm-minus-4_4-percent-despite-beating-q4-estimates-posting-first-revenue-growth-nearly-6\" target=\"_blank\">IBM -4.4% despite beating Q4 estimates, posting first revenue growth in nearly 6 years</a> (Jan. 18)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3323848-ibm-q4-earnings-call-fy18-guidance-tax-forecast-margin-erosion\" target=\"_blank\">IBM Q4 earnings call: FY18 guidance, tax forecast, and margin erosion</a> (Jan. 19)</li><li>Update: Corrected ticker movement at time of publication.</li></ul><div class=\"tiny-share-widget\" data-id=\"3323931\" data-linked=\"Analysts comment on IBM&#39;s earnings\" data-tweet=\"$IBM - Analysts comment on IBM&#39;s earnings https://seekingalpha.com/news/3323931-analysts-comment-on-ibms-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3323931-analysts-comment-on-ibms-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:29 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>29&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323929\" data-ts=\"1516385760\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMPH\" target=\"_blank\">AMPH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323929-u-s-justice-department-may-seek-damages-from-generic-drugmakers-for-price-fixing\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">U.S. Justice Department may seek damages from generic drugmakers for price-fixing</a></h4><ul><li>Some generic drug firms are under modest pressure in apparent response to a speech delivered by U.S. Department of Justice antitrust division chief Makan Delrahim earlier today at George Mason University's law school. He said the DOJ may sue generic drug companies to recover damages over alleged price-fixing, adding that if taxpayers were overcharged due to collusion to raise prices, then seeking remedies may be appropriate.</li><li>The antitrust division and state AGs are involved in an ongoing investigation into alleged price-fixing by generic drugmakers.</li><li>Source: Bloomberg</li><li>Selected tickers: (<a href='https://seekingalpha.com/symbol/AMPH' title='Amphastar'>AMPH</a> <font color='red'>-0.4%</font>)(<a href='https://seekingalpha.com/symbol/ANIP' title='ANI Pharmaceuticals, Inc.'>ANIP</a> <font color='green'>+0.2%</font>)(<a href='https://seekingalpha.com/symbol/ACRS' title='Aclaris Therapeutics'>ACRS</a> <font color='green'>+1.9%</font>)(<a href='https://seekingalpha.com/symbol/AKRX' title='Akorn, Inc.'>AKRX</a> <font color='red'>-0.4%</font>)(<a href='https://seekingalpha.com/symbol/COLL' title='Collegium Pharmaceutical'>COLL</a> <font color='green'>+13.3%</font>)(<a href='https://seekingalpha.com/symbol/RDY' title='Dr. Reddy&#39;s Laboratories Limited'>RDY</a> <font color='green'>+1.5%</font>)(<a href='https://seekingalpha.com/symbol/EGRX' title='Eagle Pharmaceuticals Inc.'>EGRX</a> <font color='red'>-0.3%</font>)(IPXL <font color='red'>-1.9%</font>)(<a href='https://seekingalpha.com/symbol/LCI' title='Lannett Company, Inc'>LCI</a> <font color='red'>-0.2%</font>)(<a href='https://seekingalpha.com/symbol/MYL' title='Mylan Inc'>MYL</a> <font color='red'>-0.3%</font>)(<a href='https://seekingalpha.com/symbol/PRGO' title='Perrigo Company'>PRGO</a> <font color='green'>+0.1%</font>)(<a href='https://seekingalpha.com/symbol/TLGT' title='Teligent, Inc.'>TLGT</a> <font color='red'>-1.1%</font>)(<a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a> <font color='red'>-1.4%</font>)(<a href='https://seekingalpha.com/symbol/ENDP' title='Endo International plc'>ENDP</a> <font color='red'>-4.8%</font>)(<a href='https://seekingalpha.com/symbol/MNTA' title='Momenta Pharmaceuticals, Inc.'>MNTA</a> <font color='green'>+6.4%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3323929\" data-linked=\"U.S. Justice Department may seek damages from generic drugmakers for price-fixing\" data-tweet=\"$AMPH $AMPH $ANIP - U.S. Justice Department may seek damages from generic drugmakers for price-fixing https://seekingalpha.com/news/3323929-u-s-justice-department-may-seek-damages-from-generic-drugmakers-for-price-fixing?source=tweet\" data-url=\"https://seekingalpha.com/news/3323929-u-s-justice-department-may-seek-damages-from-generic-drugmakers-for-price-fixing\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:16 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323928\" data-ts=\"1516385699\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SMCI\" target=\"_blank\">SMCI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323928-super-microplus-5-on-customer-ibms-earnings-report\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Super Micro +5% on customer IBM&#39;s earnings report</a></h4><ul><li>        Super Micro Computer (NASDAQ:<a href='https://seekingalpha.com/symbol/SMCI' title='Super Micro Computer, Inc.'>SMCI</a>) benefits from the earnings report of customer IBM, which reported &ldquo;strong results&rdquo; in its systems business.</li><li>               Super Micro makes server products, and IBM accounts for about 5% of Super Micro sales, according to Bloomberg.&nbsp;</li><li>               Source: Bloomberg First Word.&nbsp;</li><li>               Super Micro Computer shares are&nbsp;<font color='green'>up 5%</font>&nbsp;to $22.58. &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3323747-ibm-minus-4_4-percent-despite-beating-q4-estimates-posting-first-revenue-growth-nearly-6\" target=\"_blank\">IBM -4.4% despite beating Q4 estimates, posting first revenue growth in nearly 6 years</a> (Jan. 18)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3323848-ibm-q4-earnings-call-fy18-guidance-tax-forecast-margin-erosion\" target=\"_blank\">IBM Q4 earnings call: FY18 guidance, tax forecast, and margin erosion</a> (Jan. 19)</li></ul><div class=\"tiny-share-widget\" data-id=\"3323928\" data-linked=\"Super Micro +5% on customer IBM&#39;s earnings report\" data-tweet=\"$SMCI - Super Micro +5% on customer IBM&#39;s earnings report https://seekingalpha.com/news/3323928-super-microplus-5-on-customer-ibms-earnings-report?source=tweet\" data-url=\"https://seekingalpha.com/news/3323928-super-microplus-5-on-customer-ibms-earnings-report\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:14 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323923\" data-ts=\"1516384856\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NCNA\" target=\"_blank\">NCNA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323923-nucanas-lead-candidate-shows-positive-effect-in-early-stage-biliary-tract-cancer-study-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NuCana&#39;s lead candidate shows positive effect in early-stage biliary tract cancer study; shares ahead 59%</a></h4><ul><li>Thinly traded NuCana (<a href='https://seekingalpha.com/symbol/NCNA' title='NuCana plc'>NCNA</a> <font color='green'>+59%</font>) is up big, albeit on modest volume, on the heels of its <a href=\"https://seekingalpha.com/pr/17051416-nucana-announces-promising-clinical-data-asco-gi-nucminus-1031-acelarin-front-line-treatment\" target=\"_blank\">announcement </a>of encouraging interim data from a Phase 1b clinical trial assessing lead candidate Acelarin, combined with the chemo agent cisplatin, for the first-line treatment of advanced biliary tract cancer. The results were presented at the ASCO-GI Symposium in San Francisco.</li><li>Patients receiving Acelarin and cisplatin on days one and eight of a three-week cycle showed a disease control rate of 63% (n=5/8), including one complete responder, three partial responders and one with stable disease. The one with stable cancer was initially considered unsuitable for surgical resection but was subsequently operated on with complete tumor removal.</li><li>The company says lead candidate&nbsp;<a href=\"http://www.nucana.com/protides.html#acelarin\" target=\"_blank\">Acelarin&nbsp;</a>is designed to replace the chemo agent gemcitabine in certain cancers by virtue of its ability to overcome key cancer resistance mechanisms. It is based on its ProTide technology which improves the effectiveness and safety profile of common chemo agents.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3312411-mid-stage-study-underway-nucanas-acelarin-platinum-resistant-ovarian-cancer\" target=\"_blank\">Mid-stage study underway for NuCana's Acelarin in platinum-resistant ovarian cancer</a> (Nov. 15, 2017)</li></ul><div class=\"tiny-share-widget\" data-id=\"3323923\" data-linked=\"NuCana&#39;s lead candidate shows positive effect in early-stage biliary tract cancer study; shares ahead 59%\" data-tweet=\"$NCNA - NuCana&#39;s lead candidate shows positive effect in early-stage biliary tract cancer study; shares ahead 59% https://seekingalpha.com/news/3323923-nucanas-lead-candidate-shows-positive-effect-in-early-stage-biliary-tract-cancer-study-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3323923-nucanas-lead-candidate-shows-positive-effect-in-early-stage-biliary-tract-cancer-study-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323922\" data-ts=\"1516384305\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HHS\" target=\"_blank\">HHS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323922-harte-hanks-reducing-executive-team-cto-coo-departs\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Harte Hanks reducing executive team as CTO/COO departs</a></h4><ul>   <li>Harte Hanks (<a href=\"http://seekingalpha.com/symbol/HHS\" target=\"_blank\">HHS</a> <font color='red'>-8.7%</font>) will downsize its executive team after a key exec departs for other opportunities.</li>    <li>Shirish Lal, executive VP and chief operating officer/chief technology officer, has resigned effective Jan. 31, 2018, according to an <a href=\"https://seekingalpha.com/filing/3836073\" target=\"_blank\">SEC filing</a>.</li>    <li>Rather than replace him, his responsibilities will be moved to CEO Karen Puckett, Chief Marketing Officer Frank Grillo, and Chief Financial Officer Jon Biro. \"The time is right to streamline\" the leadership, Puckett says.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3323922\" data-linked=\"Harte Hanks reducing executive team as CTO/COO departs\" data-tweet=\"$HHS - Harte Hanks reducing executive team as CTO/COO departs https://seekingalpha.com/news/3323922-harte-hanks-reducing-executive-team-cto-coo-departs?source=tweet\" data-url=\"https://seekingalpha.com/news/3323922-harte-hanks-reducing-executive-team-cto-coo-departs\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:51 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323920\" data-ts=\"1516383925\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323920-midday-gainers-losers-1-19-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers (1/19/2018)</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/FORD' title='Forward Industries, Inc.'>FORD</a> <font color='green'>+160%</font>. <a href='https://seekingalpha.com/symbol/NCNA' title='NuCana plc'>NCNA</a> <font color='green'>+44%</font>. <a href='https://seekingalpha.com/symbol/ORPN' title='Bio Blast Pharma'>ORPN</a> <font color='green'>+25%</font>. <a href='https://seekingalpha.com/symbol/RNN' title='Rexahn Pharmaceuticals Inc'>RNN</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/SIEN' title='Sientra'>SIEN</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/DXR' title='Daxor Corp'>DXR</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/CKPT' title='CHECKPOINT THERAPEUTICS'>CKPT</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/COLL' title='Collegium Pharmaceutical'>COLL</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/MNTA' title='Momenta Pharmaceuticals, Inc.'>MNTA</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/RCG' title='RENN Global Entrepreneurs Fund'>RCG</a> <font color='green'>+12%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/PAVM' title='PAVmed Inc.'>PAVM</a> <font color='red'>-27%</font>. ARGS <font color='red'>-21%</font>. <a href='https://seekingalpha.com/symbol/SGLB' title='Sigma Labs, Inc.'>SGLB</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/MNGA' title='MagneGas Corporation'>MNGA</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/GNC' title='GNC Holdings, Inc.'>GNC</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/CVO' title='Cenveo, Inc.'>CVO</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/HHS' title='Harte Hanks Inc.'>HHS</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/DFBG-OLD' title='Differential Brands Group Inc.'>DFBG-OLD</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/RCON' title='Recon Technology, Ltd.'>RCON</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/DYNT' title='Dynatronics Corporation'>DYNT</a> <font color='red'>-8%</font>.  ;</li> </ul><div class=\"tiny-share-widget\" data-id=\"3323920\" data-linked=\"Midday Gainers / Losers (1/19/2018)\" data-tweet=\"$FORD $NCNA $ENLV - Midday Gainers / Losers (1/19/2018) https://seekingalpha.com/news/3323920-midday-gainers-losers-1-19-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3323920-midday-gainers-losers-1-19-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:45 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323917\" data-ts=\"1516383323\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MNTA\" target=\"_blank\">MNTA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323917-momenta-pharma-hits-volatility-circuit-breaker-on-reports-may-explore-strategic-options\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Momenta Pharma hits volatility circuit breaker on reports that it may explore strategic options; shares up 11%</a></h4><ul><li>Nasdaq temporarily suspended trading in Momenta Pharmaceuticals (<a href='https://seekingalpha.com/symbol/MNTA' title='Momenta Pharmaceuticals, Inc.'>MNTA</a> <font color='green'>+10.6%</font>) due to volatility. Shares spiked on <a href=\"https://stocknews.com/news/mnta-headlines-that-the-company-may-be-exploring-strategic-options/\" target=\"_blank\">reports </a>that it may explore strategic alternatives.</li><li>The company has two products on the market: <a href=\"http://www.momentapharma.com/products/glatopa.php\" target=\"_blank\">Glatopa </a>(glatiramer acetate injection), a generic version of Teva's MS med Copaxone and <a href=\"http://www.momentapharma.com/products/enoxaparin.php\" target=\"_blank\">Enoxaparin Sodium Injectio</a>n, a generic version of Sanofi's deep vein thrombosis med Lovenox.</li></ul><div class=\"tiny-share-widget\" data-id=\"3323917\" data-linked=\"Momenta Pharma hits volatility circuit breaker on reports that it may explore strategic options; shares up 11%\" data-tweet=\"$MNTA - Momenta Pharma hits volatility circuit breaker on reports that it may explore strategic options; shares up 11% https://seekingalpha.com/news/3323917-momenta-pharma-hits-volatility-circuit-breaker-on-reports-may-explore-strategic-options?source=tweet\" data-url=\"https://seekingalpha.com/news/3323917-momenta-pharma-hits-volatility-circuit-breaker-on-reports-may-explore-strategic-options\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323916\" data-ts=\"1516382293\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TYME\" target=\"_blank\">TYME</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323916-tyme-techs-lead-candidate-shows-positive-effect-in-early-stage-pancreatic-cancer-study-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tyme Tech&#39;s lead candidate shows positive effect in early-stage pancreatic cancer study; shares ahead 2%</a></h4><ul><li><a href=\"https://seekingalpha.com/pr/17051403-tyme-announces-positive-efficacy-data-smminus-88-pancreatic-cancer-2018-asco-gastrointestinal\" target=\"_blank\">Results </a>from a 10-subject study assessing Tyme Technologies' (<a href='https://seekingalpha.com/symbol/TYME' title='Tyme Technologies, Inc.'>TYME</a> <font color='green'>+1.6%</font>) lead candidate SM-88 in patients with advanced metastatic/recurrent pancreatic cancer showed a treatment effect. The data were presented at the ASCO-GI Symposium in San Francisco.</li><li>The overall response rate &#40;ORR&#41; was 30% (n=3/10). 40% (n=4/10) survived more than 12 months. 100% (n=10/10) reported stable or reduced pain scores during their first cycle of treatment.</li><li>A Phase 2 study should launch later this year. A <a href=\"https://clinicaltrials.gov/ct2/show/NCT02796898?term=Tyme&amp;recrs=abc&amp;rank=1\" target=\"_blank\">Phase 2 </a>in prostate cancer is currently recruiting patients.</li><li><a href=\"https://www.tymeinc.com/sm-88/what-is-sm-88/\" target=\"_blank\">SM-88</a> is a combination therapy that uses a proprietary dysfunctional tyrosine derivative to interrupt the metabolic processes of cancer cells, breaking down their defenses and making them vulnerable to oxidative stress and death.</li></ul><div class=\"tiny-share-widget\" data-id=\"3323916\" data-linked=\"Tyme Tech&#39;s lead candidate shows positive effect in early-stage pancreatic cancer study; shares ahead 2%\" data-tweet=\"$TYME - Tyme Tech&#39;s lead candidate shows positive effect in early-stage pancreatic cancer study; shares ahead 2% https://seekingalpha.com/news/3323916-tyme-techs-lead-candidate-shows-positive-effect-in-early-stage-pancreatic-cancer-study-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3323916-tyme-techs-lead-candidate-shows-positive-effect-in-early-stage-pancreatic-cancer-study-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:18 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323914\" data-ts=\"1516381610\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323914-consumer-top-gainers-losers-of-12-00-pm-1-19-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm (1/19/2018)</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/FORD' title='Forward Industries, Inc.'>FORD</a> <font color='green'>+164%</font>. <a href='https://seekingalpha.com/symbol/NBEV' title='New Age Beverages Corporation'>NBEV</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/FOSL' title='Fossil, Inc.'>FOSL</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/VOXX' title='VOXX International Corp.'>VOXX</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/DFBG-OLD' title='Differential Brands Group Inc.'>DFBG-OLD</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/ICON' title='Iconix Brand Group, Inc.'>ICON</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3323914\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm (1/19/2018)\" data-tweet=\"$FORD $NBEV $FOSL - Consumer - Top Gainers / Losers as of 12:00 pm (1/19/2018) https://seekingalpha.com/news/3323914-consumer-top-gainers-losers-of-12-00-pm-1-19-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3323914-consumer-top-gainers-losers-of-12-00-pm-1-19-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:06 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323910\" data-ts=\"1516381011\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APO\" target=\"_blank\">APO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323910-underwhelming-debut-for-adt\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Underwhelming debut for ADT</a></h4><ul><li>Brought public again by Apollo Global (<a href='https://seekingalpha.com/symbol/APO' title='Apollo Global Management, LLC'>APO</a> <font color='red'>-1.6%</font>), ADT (NYSE:<a href='https://seekingalpha.com/symbol/ADT' title='The ADT Corporation'>ADT</a>) priced its IPO at&nbsp; $14 per share vs. the hoped-for $17-$19 range. In early post-IPO action, shares are trading hands at $12.71.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3322948-warnings-adt-ahead-ipo\" target=\"_blank\">Warnings on ADT ahead of IPO</a> (Jan. 16)</li></ul><div class=\"tiny-share-widget\" data-id=\"3323910\" data-linked=\"Underwhelming debut for ADT\" data-tweet=\"$APO $APO $ADT - Underwhelming debut for ADT https://seekingalpha.com/news/3323910-underwhelming-debut-for-adt?source=tweet\" data-url=\"https://seekingalpha.com/news/3323910-underwhelming-debut-for-adt\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323907\" data-ts=\"1516380248\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XON\" target=\"_blank\">XON</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323907-intrexon-raises-86m-in-equity-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intrexon raises $86M in equity offering</a></h4><ul><li>Intrexon (<a href='https://seekingalpha.com/symbol/XON' title='Intrexon Corp'>XON</a> <font color='red'>-6.1%</font>) <a href=\"https://seekingalpha.com/pr/17051360-intrexon-announces-closing-public-offering-common-stock-exercise-option-underwriters\" target=\"_blank\">closes </a>its public stock offering, raising $86M via the sale of 6.9M common shares at $12.50 per share. Underwriters fully exercised their option to buy 900K shares.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3323242-intrexon-prices-stock-offering-12_50-shares-2-percent\" target=\"_blank\">Intrexon prices stock offering at $12.50; shares up 2%</a> (Jan. 17)</li></ul><div class=\"tiny-share-widget\" data-id=\"3323907\" data-linked=\"Intrexon raises $86M in equity offering\" data-tweet=\"$XON - Intrexon raises $86M in equity offering https://seekingalpha.com/news/3323907-intrexon-raises-86m-in-equity-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3323907-intrexon-raises-86m-in-equity-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:44 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323906\" data-ts=\"1516379752\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NBEV\" target=\"_blank\">NBEV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323906-new-age-beverages-building-on-gains-from-military-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">New Age Beverages building on gains from military deal</a></h4><ul>   <li>New Age Beverages (<a href=\"http://seekingalpha.com/symbol/NBEV\" target=\"_blank\">NBEV</a> <font color='green'>+10%</font>) is on its second day of double-digit gains after its deal to get its drinks into <a href=\"https://seekingalpha.com/pr/17049788-new-age-beverages-expands-distribution-entire-healthy-portfolio-worldwide-us-military\" target=\"_blank\">U.S. military commissaries</a> worldwide.</li>    <li>Volume at 1.29M shares has already surpassed average volume.</li>    <li>The company now expects to reach a population of 25M people across more than 30 countries (more than 3,300 outlets, counting commissaries and exchanges) with some 21 total SKUs, including brands like XingTea, Coco-Libre, Marley, and B&uacute;cha Live Kombucha.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3323906\" data-linked=\"New Age Beverages building on gains from military deal\" data-tweet=\"$NBEV - New Age Beverages building on gains from military deal https://seekingalpha.com/news/3323906-new-age-beverages-building-on-gains-from-military-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3323906-new-age-beverages-building-on-gains-from-military-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:35 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323901\" data-ts=\"1516379559\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IOVA\" target=\"_blank\">IOVA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323901-iovance-adds-to-rally-up-12\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Iovance adds to rally, up 12%</a></h4><ul><li>Cell therapy outfit Iovance Biotherapeutics (<a href='https://seekingalpha.com/symbol/IOVA' title='Iovance Biotherapeutics, Inc.'>IOVA</a> <font color='green'>+11.7%</font>) is up on double normal volume. Shares have rallied&nbsp;<font color='green'>140%</font>&nbsp;since August. No particular recent news accounts for the move, although the action in Juno Therapeutics (<a href='https://seekingalpha.com/symbol/JUNO' title='Juno Therapeutics'>JUNO</a> <font color='red'>-2.8%</font>) is probably a factor.</li><li>Iovance develops cancer treatments based on <a href=\"http://www.iovance.com/our-science/til-platform/\" target=\"_blank\">tumor infiltrating lymphocytes</a> &#40;TIL&#41;. In a process similar to Juno's CAR-T therapies, TIL are extracted from the patient, expanded <em>ex vivo,&nbsp;</em>then reinfused where they attack and kill cancer cells.</li><li>A couple of months ago, the company announced positive data from a mid-stage study of lead candidate LN-144 in metastatic melanoma.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3310592-iovances-lead-candidate-shows-positive-effect-mid-stage-melanoma-study-shares-ahead-7-percent\" target=\"_blank\">Iovance's lead candidate shows positive effect in mid-stage melanoma study; shares ahead 7% premarket</a> (Nov. 9, 2017)</li></ul><div class=\"tiny-share-widget\" data-id=\"3323901\" data-linked=\"Iovance adds to rally, up 12%\" data-tweet=\"$IOVA $IOVA $JUNO - Iovance adds to rally, up 12% https://seekingalpha.com/news/3323901-iovance-adds-to-rally-up-12?source=tweet\" data-url=\"https://seekingalpha.com/news/3323901-iovance-adds-to-rally-up-12\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:32 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323903\" data-ts=\"1516379192\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAPL\" target=\"_blank\">AAPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323903-apple-suppliers-drop-key-analyst-lowers-iphone-x-lifetime-sales-forecast\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Apple, suppliers drop as key analyst lowers iPhone X lifetime sales forecast</a></h4><ul><li>        KGI Securities analyst Ming-Chi Kuo <a href=\"https://www.bloomberg.com/news/articles/2018-01-19/key-analyst-cuts-iphone-x-estimates-sees-production-end-in-2018\" target=\"_blank\">lowers</a> the lifetime sales forecast for Apple&rsquo;s (<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a> <font color='red'>-0.6%</font>) iPhone X from 80M to 62M units.</li><li>               Kuo expects production of the premium model to stop sometime in 2018 as Apple prepares to roll out new versions in 2H.&nbsp;</li><li>               The analyst cites weakness in China for the lowering, saying that high-end Chinese users do love larger screens, but the notched design and lack of compatible apps made the iPhone X seem smaller and overpriced.&nbsp;</li><li>               Bloomberg Intelligence analyst Woo Jin Ho says Apple chipmakers will likely have a cautious approach to Q1 as the iPhone cycle enters a seasonally weak period. (Source: Bloomberg First Word.)&nbsp;</li><li>               Suppliers on the move: Qorvo (<a href='https://seekingalpha.com/symbol/QRVO' title='Qorvo, Inc'>QRVO</a> <font color='red'>-4.2%</font>), Cirrus Logic (<a href='https://seekingalpha.com/symbol/CRUS' title='Cirrus Logic, Inc.'>CRUS</a> <font color='red'>-2.4%</font>), &nbsp;Skyworks Solutions (<a href='https://seekingalpha.com/symbol/SWKS' title='Skyworks Solutions, Inc.'>SWKS</a> <font color='red'>-2.8%</font>), Broadcom (<a href='https://seekingalpha.com/symbol/AVGO' title='Broadcom Limited'>AVGO</a> <font color='red'>-0.8%</font>), and Lumentum (<a href='https://seekingalpha.com/symbol/LITE' title='Lumentum Holdings Inc.'>LITE</a> <font color='red'>-5%</font>).&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3323609-apple-still-owes-eu-tax-bill-payments-start-march\" target=\"_blank\">Apple still owes EU tax bill, payments start in March</a> (Jan. 18)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3323673-tsmc-expects-iphone-shipments-drop-softened-crypto-mining-boost\" target=\"_blank\">TSMC expects iPhone shipments to drop, softened by crypto mining boost</a> (Jan. 18)</li></ul><div class=\"tiny-share-widget\" data-id=\"3323903\" data-linked=\"Apple, suppliers drop as key analyst lowers iPhone X lifetime sales forecast\" data-tweet=\"$AAPL $AAPL $QRVO - Apple, suppliers drop as key analyst lowers iPhone X lifetime sales forecast https://seekingalpha.com/news/3323903-apple-suppliers-drop-key-analyst-lowers-iphone-x-lifetime-sales-forecast?source=tweet\" data-url=\"https://seekingalpha.com/news/3323903-apple-suppliers-drop-key-analyst-lowers-iphone-x-lifetime-sales-forecast\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>113&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323897\" data-ts=\"1516378481\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/Z\" target=\"_blank\">Z</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323897-stifel-resumes-zillow-hold-sees-price-downside\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stifel resumes Zillow at Hold, sees price downside</a></h4><ul>   <li>Zillow Group (<a href=\"http://seekingalpha.com/symbol/Z\" target=\"_blank\">Z</a> <font color='red'>-3.7%</font>) has had coverage resumed at Stifel with a Hold rating, and a price target looking to the downside.</li>    <li>The firm's target is set at $38, implying 13% downside from yesterday's close.</li>    <li>Stifel's back in an nearly evenly split fray, with analysts divided between Hold and Buy calls.</li>    <li>Shares are <font color='red'>off 7.3%</font> over the past six months, but <font color='green'>up 15.6%</font> over the past 12.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3323897\" data-linked=\"Stifel resumes Zillow at Hold, sees price downside\" data-tweet=\"$Z - Stifel resumes Zillow at Hold, sees price downside https://seekingalpha.com/news/3323897-stifel-resumes-zillow-hold-sees-price-downside?source=tweet\" data-url=\"https://seekingalpha.com/news/3323897-stifel-resumes-zillow-hold-sees-price-downside\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323900\" data-ts=\"1516378126\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SCIL\" target=\"_blank\">SCIL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323900-scientific-learning-signs-agreement-to-acquire-brainmaps\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Scientific Learning signs agreement to acquire BrainMaps</a></h4><ul>     <li>Scientific Learning (<a href='https://seekingalpha.com/symbol/SCIL' title='Scientific Learning Corp.'>OTC:SCIL</a> <font color='green'>+10.2%</font>) has signed a definitive agreement with Brain Maps Technology Co. Ltd. to acquire BrainMaps (Shanghai).</li>     <li>BrainMaps combines Scientific Learning&rsquo;s patented language learning technologies and a unique Online-to-Offline (O2O) methodology.</li>     <li>&ldquo;China is a country where education-focused parents spend on average more than 30 percent of household income on education, and where 84 percent of families spend money on after-school tutoring,&rdquo; said Robert C. Bowen, CEO of Scientific Learning. &ldquo;BrainMaps&rsquo; recent success is emblematic of the strong demand for English language learning solutions for students in China, and this acquisition will enable us to further accelerate BrainMaps&rsquo; growth there.&rdquo;</li> </ul><div class=\"tiny-share-widget\" data-id=\"3323900\" data-linked=\"Scientific Learning signs agreement to acquire BrainMaps\" data-tweet=\"$SCIL - Scientific Learning signs agreement to acquire BrainMaps https://seekingalpha.com/news/3323900-scientific-learning-signs-agreement-to-acquire-brainmaps?source=tweet\" data-url=\"https://seekingalpha.com/news/3323900-scientific-learning-signs-agreement-to-acquire-brainmaps\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323894\" data-ts=\"1516377812\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ORPN\" target=\"_blank\">ORPN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323894-bioblast-pharma-rollercoaster-continues-shares-up-31\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bioblast Pharma rollercoaster continues, shares up 31%</a></h4><ul><li>The extraordinary volatility in thinly traded nano cap Bioblast Pharma (<a href='https://seekingalpha.com/symbol/ORPN' title='Bio Blast Pharma'>ORPN</a> <font color='green'>+31.4%</font>) is on display again today on a 12x surge in volume. Shares were up&nbsp;<font color='green'>81%</font>&nbsp;intraday before retracing. Yesterday, shares were up as much as&nbsp;<font color='green'>128%</font>&nbsp;before reversing and completing a roundtrip by the close.</li><li>CEO Prof. Zohar Argov, M.D., <a href=\"https://www.benzinga.com/movers/18/01/11052924/bioblast-shares-up-34-for-session-on-wed-co-ceo-reassured-benzinga-no-news-to-\" target=\"_blank\">told Benzinga</a> that there was no news justifying the action.</li></ul><div class=\"tiny-share-widget\" data-id=\"3323894\" data-linked=\"Bioblast Pharma rollercoaster continues, shares up 31%\" data-tweet=\"$ORPN $ENLV - Bioblast Pharma rollercoaster continues, shares up 31% https://seekingalpha.com/news/3323894-bioblast-pharma-rollercoaster-continues-shares-up-31?source=tweet\" data-url=\"https://seekingalpha.com/news/3323894-bioblast-pharma-rollercoaster-continues-shares-up-31\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:03 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323877\" data-ts=\"1516377697\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323877-healthcare-top-5-gainers-losers-of-11-00-1-19-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am (1/19/2018)</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/ORPN' title='Bio Blast Pharma'>ORPN</a> <font color='green'>+33%</font>. <a href='https://seekingalpha.com/symbol/COLL' title='Collegium Pharmaceutical'>COLL</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/SIEN' title='Sientra'>SIEN</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/IOVA' title='Iovance Biotherapeutics, Inc.'>IOVA</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/CHFS' title='CHF Solutions, Inc.'>CHFS</a> <font color='green'>+11%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/PAVM' title='PAVmed Inc.'>PAVM</a> <font color='red'>-28%</font>. ARGS <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/DYNT' title='Dynatronics Corporation'>DYNT</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/ONTX' title='Onconova Therapeutics'>ONTX</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3323877\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am (1/19/2018)\" data-tweet=\"$ENLV $COLL $SIEN - Healthcare - Top 5 Gainers / Losers as of 11:00 am (1/19/2018) https://seekingalpha.com/news/3323877-healthcare-top-5-gainers-losers-of-11-00-1-19-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3323877-healthcare-top-5-gainers-losers-of-11-00-1-19-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323892\" data-ts=\"1516377188\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KSS\" target=\"_blank\">KSS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323892-kohls-price-target-upped-to-100-jefferies-amazon-partnership-ramps\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kohl&#39;s price target upped to $100 at Jefferies as Amazon partnership ramps</a></h4><ul>     <li>Kohl's (<a href='https://seekingalpha.com/symbol/KSS' title='Kohl&#39;s Corporation'>KSS</a> <font color='green'>+2.5%</font>) moves higher after Jefferies <a href=\"https://www.cnbc.com/2018/01/19/kohls-shares-could-pop-50-percent-as-amazon-partnership-ramps-up.html\" target=\"_blank\">raises its stock price target to $100</a> from $66, citing the company's partnership with Amazon (<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a> <font color='green'>+0.3%</font>) as a \"win for both companies.\"</li>     <li>\"We anticipate the pilot to roll out nationally and provide KSS stores with stronger traffic and is a nice added convenience for AMZN shoppers,\" writes Jefferies analyst Randal Konik.</li><li>KSS gets an added benefit from its stores being located off-mall where  customer traffic is better, Konik says, expecting a further boost as peers  such as J.C. Penney and Macy's shutter stores; he also thinks a lower corporate tax rate will benefit the company and drive earnings higher.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3323892\" data-linked=\"Kohl&#39;s price target upped to $100 at Jefferies as Amazon partnership ramps\" data-tweet=\"$KSS $KSS $AMZN - Kohl&#39;s price target upped to $100 at Jefferies as Amazon partnership ramps https://seekingalpha.com/news/3323892-kohls-price-target-upped-to-100-jefferies-amazon-partnership-ramps?source=tweet\" data-url=\"https://seekingalpha.com/news/3323892-kohls-price-target-upped-to-100-jefferies-amazon-partnership-ramps\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323887\" data-ts=\"1516376784\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TCON\" target=\"_blank\">TCON</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323887-investors-unmoved-tracon-pharmas-trc105-in-mid-stage-liver-cancer-study-shares-down-7\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Investors unmoved with TRACON Pharma&#39;s TRC105 in mid-stage liver cancer study; shares down 7%</a></h4><ul><li><a href=\"https://seekingalpha.com/pr/17051330-tracon-pharmaceuticals-announces-positive-data-ongoing-phase-1b-2-trial-trc105-hepatocellular\" target=\"_blank\">Preliminary results</a> from an ongoing Phase 1b/2 clinical trial assessing TRACON Pharmaceuticals' (<a href='https://seekingalpha.com/symbol/TCON' title='Tracon Pharmaceuticals'>TCON</a> <font color='red'>-6.6%</font>)&nbsp;lead candidate TRC105, combined with Bayer's NEXAVAR (sorafenib), in patients with advanced hepatocellular carcinoma &#40;HCC&#41; demonstrated a treatment effect compared to NEXAVAR alone. The data were presented at the ASCO-GI Symposium in San Francisco.</li><li>Partial responses were observed in 25% (n=2/8) of patients while 38% (n=3/8) showed at least a 50% reduction in an HCC tumor marker called alpha fetoprotein &#40;AFP&#41;.</li><li>Investors appear disappointed with the results, possibly by the low number of data points thus far.</li><li>Results from a pivotal <a href=\"http://www.nejm.org/doi/full/10.1056/NEJMoa0708857#t=article\" target=\"_blank\">Phase 3 study</a> supporting Bayer's marketing application showed HCC patients treated with NEXAVAR experienced median overall survival &#40;OS&#41; of 10.7 months (n=143) and median progression-free survival &#40;PFS&#41; of 5.5 months (n=107), the co-primary endpoints. There was a 2.3% partial response rate (n=7/299) while 70.6% had stable disease (n=211/299), implying a disease control rate of 72.9% (n=218/299). The addition of TRC105, at least preliminarily, produced a ten-fold increase in response rate.</li><li>Enrollment of ~33 subjects should be completed by year-end.</li><li><a href=\"http://www.traconpharma.com/trc105.php\" target=\"_blank\">TRC105&nbsp;</a>is an antibody that binds to a protein called endoglin which is overexpressed on proliferating endothelial cells that play an essential role in angiogenesis (formation of new blood vessels).</li></ul><div class=\"tiny-share-widget\" data-id=\"3323887\" data-linked=\"Investors unmoved with TRACON Pharma&#39;s TRC105 in mid-stage liver cancer study; shares down 7%\" data-tweet=\"$TCON - Investors unmoved with TRACON Pharma&#39;s TRC105 in mid-stage liver cancer study; shares down 7% https://seekingalpha.com/news/3323887-investors-unmoved-tracon-pharmas-trc105-in-mid-stage-liver-cancer-study-shares-down-7?source=tweet\" data-url=\"https://seekingalpha.com/news/3323887-investors-unmoved-tracon-pharmas-trc105-in-mid-stage-liver-cancer-study-shares-down-7\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323891\" data-ts=\"1516376594\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LOW\" target=\"_blank\">LOW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323891-lowes-riding-price-target-hikes-based-on-promising-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lowe&#39;s riding price target hikes based on promising 2018</a></h4><ul>   <li>Lowe's (<a href=\"http://seekingalpha.com/symbol/LOW\" target=\"_blank\">LOW</a> <font color='green'>+3.6%</font>) has gotten a price target hike from BTIG, the latest in a set of target raises this week.</li>    <li>BTIG's Alan Rifkin boosted his target to $115 from $95, pointing to improved execution and a robust home improvement outlook for 2018 (including effects of hurricane recovery).</li>        <li>It's also likely to make gains in appliances as Sears continues closing stores, Rifkin says. (h/t Bloomberg)</li>    <li>Consumer Edge's <a href=\"https://seekingalpha.com/news/3322823-consumer-edge-research-sees-plus-20-percent-upside-lowes\" target=\"_blank\">$124 price target</a> implies 18% upside from today's pricing.</li><li>Credit Suisse had raised it price target to $116 from $88 on Tuesday.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3323870-lowes-names-three-new-board-members-talks-activist-investor\" target=\"_blank\">Lowe's names three new board members after talks with activist investor</a> (Jan. 19 2018)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3323891\" data-linked=\"Lowe&#39;s riding price target hikes based on promising 2018\" data-tweet=\"$LOW - Lowe&#39;s riding price target hikes based on promising 2018 https://seekingalpha.com/news/3323891-lowes-riding-price-target-hikes-based-on-promising-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3323891-lowes-riding-price-target-hikes-based-on-promising-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:43 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323888\" data-ts=\"1516375658\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ANF\" target=\"_blank\">ANF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323888-abercrombie-fitch-upgraded-to-buy-argus-on-turnaround-plan\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Abercrombie &amp; Fitch upgraded to Buy at Argus on turnaround plan</a></h4><ul>     <li>Abercrombie &amp;&nbsp;FItch (<a href='https://seekingalpha.com/symbol/ANF' title='Abercrombie & Fitch'>ANF</a> <font color='green'>+3.5%</font>) is sharply higher after Argus Research <a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/18/01/11052144/argus-turns-bullish-on-abercrombie-sees-upside-to-25\" target=\"_blank\">upgrades shares to Buy</a> from Hold with a $25 price target, saying the company's turnaround plan is starting to see results.</li>     <li>ANF's marketing is emphasizing the company's historic association with outdoor adventure and exploration, and the firm thinks the brand's perception among young consumers has \"improved significantly,\" which should contribute to longer-term market share gains.</li>     <li>Shares have rebounded to nearly $20 after two straight quarters of earnings surprises, but Argus believes ANF still looks attractive as it continues to trade at a discount to its peers and below historical average multiples.</li></ul><div class=\"tiny-share-widget\" data-id=\"3323888\" data-linked=\"Abercrombie &amp; Fitch upgraded to Buy at Argus on turnaround plan\" data-tweet=\"$ANF - Abercrombie &amp; Fitch upgraded to Buy at Argus on turnaround plan https://seekingalpha.com/news/3323888-abercrombie-fitch-upgraded-to-buy-argus-on-turnaround-plan?source=tweet\" data-url=\"https://seekingalpha.com/news/3323888-abercrombie-fitch-upgraded-to-buy-argus-on-turnaround-plan\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323886\" data-ts=\"1516374832\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NKE\" target=\"_blank\">NKE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323886-nikeplus-3-wedbush-upgrades-says-new-footwear-styles-notably-higher\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nike +3% as Wedbush upgrades, says new footwear styles &#39;notably higher&#39;</a></h4><ul>     <li>Nike (<a href='https://seekingalpha.com/symbol/NKE' title='Nike Inc.'>NKE</a> <font color='green'>+3.3%</font>) is off to a strong start after Wedbush <a href=\"https://www.cnbc.com/2018/01/19/nike-shares-jump-analyst-predicts-rally-on-new-sneaker-sales.html\" target=\"_blank\">upgrades shares to Outperform</a> from Neutral with a $74 price target, raised from $57, foreseeing an inflection in margin and a return to growth in North America in FY 2019.</li>     <li>Wedbush believes the brand's new footwear styles are \"notably higher\" than a year ago while comparisons are easing, particularly around key categories such as basketball, and it says conversations with retailers indicate that NKE has a major opportunity to show improvement in 2018.</li>     <li>The firm believes NKE's negatives - North America weakness, gross margin walk-down - are subsiding, while the positives - product, ASP, DTC - are accelerating, and it sees sales, gross margin gains and mid-teens EPS growth as increasingly more likely in FY 2019.</li></ul><div class=\"tiny-share-widget\" data-id=\"3323886\" data-linked=\"Nike +3% as Wedbush upgrades, says new footwear styles &#39;notably higher&#39;\" data-tweet=\"$NKE - Nike +3% as Wedbush upgrades, says new footwear styles &#39;notably higher&#39; https://seekingalpha.com/news/3323886-nikeplus-3-wedbush-upgrades-says-new-footwear-styles-notably-higher?source=tweet\" data-url=\"https://seekingalpha.com/news/3323886-nikeplus-3-wedbush-upgrades-says-new-footwear-styles-notably-higher\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:13 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323885\" data-ts=\"1516374813\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SOGO\" target=\"_blank\">SOGO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323885-sogou-names-permanent-cfo\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sogou names permanent CFO</a></h4><ul>     <li>Chinese search engine Sogou (<a href=\"http://seekingalpha.com/symbol/SOGO\" target=\"_blank\">SOGO</a> <font color='green'>+2.3%</font>) has tapped Joe Zhou as its <a href=\"https://www.streetinsider.com/Corporate+News/Sogou+Inc.+%28SOGO%29+Announces+Joe+Zhou+as+Chief+Financial+Officer/13701366.html\" target=\"_blank\">chief financial officer</a>.</li>     <li>The move is effective Jan. 22. He'll replace James Deng, who came over from Sohu.com (<a href=\"http://seekingalpha.com/symbol/SOHU\" target=\"_blank\">SOHU</a> <font color='red'>-0.7%</font>) last July to guide the Sohu search offshoot through its <a href=\"https://seekingalpha.com/news/3310269-chinese-search-engine-sogou-prices-u-s-ipo-top-range\" target=\"_blank\">November IPO</a>.</li>     <li>Deng will remain as an adviser at Sogou for six months before resuming his former role at Sohu.com, still controlling shareholder of Sogou.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3323885\" data-linked=\"Sogou names permanent CFO\" data-tweet=\"$SOGO $SOGO $SOHU - Sogou names permanent CFO https://seekingalpha.com/news/3323885-sogou-names-permanent-cfo?source=tweet\" data-url=\"https://seekingalpha.com/news/3323885-sogou-names-permanent-cfo\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:13 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323882\" data-ts=\"1516374192\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IPHI\" target=\"_blank\">IPHI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323882-needham-lowers-inphi-price-target-still-27-upside\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Needham lowers Inphi price target, still a 27% upside</a></h4><ul><li>        Needham lowers its Inphi (NYSE:<a href='https://seekingalpha.com/symbol/IPHI' title='Inphi Corporation'>IPHI</a>) price target by $5 to $45 but maintains a Strong Buy rating. The new target is 27% above yesterday&rsquo;s closing price.</li><li>               Firm cited the company&rsquo;s press release Wednesday cautioning about a challenging Q1 and management comments during the Needham Growth Conference.&nbsp;</li><li>               Inphi says the near-term outlook will remain pressured by the drawdown of excess levels of TIA inventory in China. Outside of that pressure, Needham thinks the company&rsquo;s other segments remain on track. &nbsp;&nbsp;</li><li>                  Inphi shares are&nbsp;<font color='red'>down 5.1%</font>&nbsp;to $33.61.&nbsp;&nbsp; </li><li>Previously: <a href=\"https://seekingalpha.com/news/3323771-inphi-drops-6_5-percent-warning-challenging-quarter\" target=\"_blank\">Inphi drops 6.5% after warning of 'challenging' quarter</a> (Jan. 18)</li></ul><div class=\"tiny-share-widget\" data-id=\"3323882\" data-linked=\"Needham lowers Inphi price target, still a 27% upside\" data-tweet=\"$IPHI - Needham lowers Inphi price target, still a 27% upside https://seekingalpha.com/news/3323882-needham-lowers-inphi-price-target-still-27-upside?source=tweet\" data-url=\"https://seekingalpha.com/news/3323882-needham-lowers-inphi-price-target-still-27-upside\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:03 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323875\" data-ts=\"1516372949\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MLNX\" target=\"_blank\">MLNX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323875-susquehanna-positive-on-mellanox-23-upside\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Susquehanna positive on Mellanox with 23% upside</a></h4><ul><li>        Susquehanna <a href=\"https://www.streetinsider.com/Analyst+Comments/Mellanox+Technologies+%28MLNX%29+PT+Raised+to+%2480+at+Susquehanna/13701437.html\" target=\"_blank\">raises</a> its Mellanox Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/MLNX' title='Mellanox Technologies, Ltd.'>MLNX</a>) price target by $5 to $80 and maintains a Positive rating following yesterday&rsquo;s earnings report. The price target is 23% above yesterday&rsquo;s closing price.</li><li>                  Latest analyst <a href=\"https://markets.ft.com/data/equities/tearsheet/forecasts?s=MLNX:NSQ\" target=\"_blank\">recommendations</a>: 3 Buy, 3 Outperform, and 9 Hold.    </li><li>               Median price target: $72.&nbsp;</li><li>               Mellanox shares are&nbsp;<font color='green'>up 4.4%</font>&nbsp;to $67.95.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3323720-mellanox-tech-plus-5_2-percent-q4-beats-upside-revenue-guidance\" target=\"_blank\">Mellanox Tech +5.2% after Q4 beats, upside revenue guidance</a> (Jan. 18)</li></ul><div class=\"tiny-share-widget\" data-id=\"3323875\" data-linked=\"Susquehanna positive on Mellanox with 23% upside\" data-tweet=\"$MLNX - Susquehanna positive on Mellanox with 23% upside https://seekingalpha.com/news/3323875-susquehanna-positive-on-mellanox-23-upside?source=tweet\" data-url=\"https://seekingalpha.com/news/3323875-susquehanna-positive-on-mellanox-23-upside\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:42 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323873\" data-ts=\"1516372261\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SIRI\" target=\"_blank\">SIRI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323873-sirius-xmplus-2_2-deutsche-bank-buckingham-rate-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sirius XM +2.2% as Deutsche Bank, Buckingham rate a Buy</a></h4><ul>   <li>Sirius XM (NASDAQ:<a href='https://seekingalpha.com/symbol/SIRI' title='Sirius XM Holdings Inc.'>SIRI</a>) is <font color='green'>up 2.2%</font> premarket, riding an upgrade at Buy by Deutsche Bank.</li>    <li>The firm's Bryan Kraft says it's been one of the worst-performing stocks in its sector since the tax reform push in late November, and yet its net operating losses should shield near-term income taxes, which promises better long-term gains than investors expect. (h/t Bloomberg)</li>    <li>Liberty Sirius XM (NASDAQ:<a href='https://seekingalpha.com/symbol/LSXMA' title='Liberty Sirius XM Series A'>LSXMA</a>) is an even better bargain, the firm says, trading at a 20% discount to NAV; that stock is <font color='green'>up 0.2%</font> premarket and also earns an upgrade to Buy from DB.</li>    <li>Buckingham Research also <a href=\"https://www.streetinsider.com/Analyst+Comments/UPDATE%3A+Buckingham+Research+Starts+Sirius+XM+Radio+%28SIRI%29+at+Buy%2C+Likes+The+Innovation+%26+Business+Moat/13701774.html\" target=\"_blank\">started the stock at Buy</a>. Analyst Matt Harrigan says an upside scenario (realizing spectrum ownership upside among other things) puts the company's price target up to $8, or 46% upside; a downside scenario pulls fair value down to $4.65 (15% downside).</li>    <li>\"We notably allow for just ~17M in annual U.S. new car sales through 2022 - even as used car customer momentum accelerates,\" he writes, noting the 360L advanced radios gradually debuting this year \"afford particularly product appeal upside.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"3323873\" data-linked=\"Sirius XM +2.2% as Deutsche Bank, Buckingham rate a Buy\" data-tweet=\"$SIRI $SIRI $LSXMA - Sirius XM +2.2% as Deutsche Bank, Buckingham rate a Buy https://seekingalpha.com/news/3323873-sirius-xmplus-2_2-deutsche-bank-buckingham-rate-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3323873-sirius-xmplus-2_2-deutsche-bank-buckingham-rate-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:31 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>52&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323871\" data-ts=\"1516371949\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMZN\" target=\"_blank\">AMZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323871-recode-amazon-increasing-monthly-prime-cost-18\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Recode: Amazon increasing monthly Prime cost by 18%</a></h4><ul><li>        Amazon (NASDAQ:<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a>) will increase the monthly price of Amazon Prime from $10.99 to $12.99, an 18% increase, according to <a href=\"https://www.recode.net/2018/1/19/16909062/amazon-prime-monthly-price-increase-membership-two-day-shipping\" target=\"_blank\">Recod</a>e.</li><li>               Student Prime pricing will jump up a dollar per month from $5.49 to $6.49.&nbsp;</li><li>               The annual price of $99 won&rsquo;t increase and would offer an increasingly better value since the new monthly price works out to about $156 a year. Also unchanged: Standalone Prime Video membership at $8.99/month and Prime for those on government assistance at $5.99/month.&nbsp;</li><li>               The monthly payment option was seen as a way for Amazon to attract lower income individuals who couldn&rsquo;t afford the $99 Prime payment and those who wanted to test the service. But with the cheaper tiers already available for students and government assistance recipients, Amazon might have felt the $10.99 wasn&rsquo;t a sustainable price. &nbsp;&nbsp;</li><li>               Amazon shares are&nbsp;<font color='green'>up 1.6%</font>&nbsp;premarket.&nbsp;&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3323641-amazon-cancels-three-shows-looks-blockbusters-programming-shift\" target=\"_blank\">Amazon cancels three shows, looks for blockbusters in programming shift</a> (Jan. 18)</li></ul><div class=\"tiny-share-widget\" data-id=\"3323871\" data-linked=\"Recode: Amazon increasing monthly Prime cost by 18%\" data-tweet=\"$AMZN - Recode: Amazon increasing monthly Prime cost by 18% https://seekingalpha.com/news/3323871-recode-amazon-increasing-monthly-prime-cost-18?source=tweet\" data-url=\"https://seekingalpha.com/news/3323871-recode-amazon-increasing-monthly-prime-cost-18\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:25 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>78&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323870\" data-ts=\"1516371926\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LOW\" target=\"_blank\">LOW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323870-lowes-names-three-new-board-members-after-talks-activist-investor\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lowe&#39;s names three new board members after talks with activist investor</a></h4><ul>     <li>Lowe's (NYSE:<a href='https://seekingalpha.com/symbol/LOW' title='Lowe&#39;s Companies, Inc.'>LOW</a>)&nbsp;<font color='green'>+1.9%</font> premarket after <a href=\"https://seekingalpha.com/pr/17051116-lowes-announces-three-new-appointments-board-directors\" target=\"_blank\">naming two independent board members</a> with plans to appoint a third following talks with activist hedge fund D.E. Shaw.</li>     <li>The news follows a <a href=\"https://seekingalpha.com/news/3322699-activist-investor-said-take-stake-lowes\" target=\"_blank\">report last week</a> that D.E. Shaw had built an active stake in the company and was concerned about its performance compared with other home improvement retailers.</li>     <li>The board appointees are David Batchelder, co-founder of Relational Investors - reportedly <a href=\"https://www.reuters.com/article/us-lowes-board/lowes-names-two-directors-after-talks-with-activist-investor-idUSKBN1F81DB?il=0\" target=\"_blank\">recommended by D.E. Shaw</a> - and Lisa Wardell, CEO of Adtalem Global Education; Brian Rogers, chairman of T. Rowe Price Group and its former chief investment officer, also will be nominated.</li></ul><div class=\"tiny-share-widget\" data-id=\"3323870\" data-linked=\"Lowe&#39;s names three new board members after talks with activist investor\" data-tweet=\"$LOW - Lowe&#39;s names three new board members after talks with activist investor https://seekingalpha.com/news/3323870-lowes-names-three-new-board-members-after-talks-activist-investor?source=tweet\" data-url=\"https://seekingalpha.com/news/3323870-lowes-names-three-new-board-members-after-talks-activist-investor\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:25 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323868\" data-ts=\"1516371363\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323868-premarket-gainers-of-9-05-1-19-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am (1/19/2018)</a></h4><ul><li><a href='https://seekingalpha.com/symbol/FORD' title='Forward Industries, Inc.'>FORD</a> <font color='green'>+63%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/17050951-forward-industries-acquires-intelligent-product-solutions\" target=\"_blank\">acquisition</a> of&nbsp;intelligent product solutions.</li><li><a href='https://seekingalpha.com/symbol/ACOR' title='Acorda Therapeutics, Inc.'>ACOR</a> <font color='green'>+15%</font>.</li><li><a href='https://seekingalpha.com/symbol/CRBP' title='Corbus Pharmaceuticals Holdings, Inc.'>CRBP</a> <font color='green'>+13%</font>.</li><li><a href='https://seekingalpha.com/symbol/YTEN' title='Yield10 Bioscience, Inc.'>YTEN</a> <font color='green'>+11%</font>.</li><li><a href='https://seekingalpha.com/symbol/CNET' title='ChinaNet Online Holdings, Inc.'>CNET</a> <font color='green'>+10%</font>.</li><li><a href='https://seekingalpha.com/symbol/EMAN' title='eMagin Corporation'>EMAN</a> <font color='green'>+9%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/17051174-emagin-corporation-comments-preliminary-fourth-quarter-2017-revenues\" target=\"_blank\">prelim</a> revenue.</li><li><a href='https://seekingalpha.com/symbol/ATRA' title='Atara Biotherapeutics'>ATRA</a> <font color='green'>+7%</font>.</li><li><a href='https://seekingalpha.com/symbol/SQ' title='Square, Inc.'>SQ</a> <font color='green'>+5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3323868\" data-linked=\"Premarket Gainers as of 9:05 am (1/19/2018)\" data-tweet=\"$FORD $ACOR $CRBP - Premarket Gainers as of 9:05 am (1/19/2018) https://seekingalpha.com/news/3323868-premarket-gainers-of-9-05-1-19-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3323868-premarket-gainers-of-9-05-1-19-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:16 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323867\" data-ts=\"1516371340\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SYF\" target=\"_blank\">SYF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323867-synchrony-financial-down-1-after-earnings-beat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Synchrony Financial down 1% after earnings beat</a></h4><ul><li>After backing out a $160M charge thanks to the tax bill, Q4 income of $545M or $0.70 per share topped estimates by $0.07.</li><li>Net interest income up 8% Y/Y to $3.9B; loans up 7% to $82B; purchase volume up 3% to $37B; deposits up 9% to $56B.</li><li>Credit quality: Loans 30+ days past due as a percentage of total loans of 4.67% up 35 basis points Y/Y; net charge-off ratio of 5.78% up from 4.65%; allowance for loan loss ratio of 6.8% up from 5.69%.</li><li>The outlook for 2018 is for a net charge-off ratio of 5.5%-5.8% (see <a href=\"http://www.investors.synchronyfinancial.com/~/media/Files/S/Synchrony-Financial-IR-V3/reports-and-presentations/q4-2017-earnings-presentation.pdf\" target=\"_blank\">presentation slides</a>), perhaps disappointing to those hoping for something closer to the low-to-mid 5% range.</li><li><a href='https://seekingalpha.com/symbol/SYF' title='Synchrony Financial'>SYF</a>&nbsp;<font color='red'>-1.1%</font>&nbsp;premarket, and now&nbsp;<font color='red'>off more than 4%</font>&nbsp;in 2018.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3323804-synchrony-financial-beats-0_07-misses-revenue\" target=\"_blank\">Synchrony Financial beats by $0.07, misses on revenue</a> (Jan. 19)</li></ul><div class=\"tiny-share-widget\" data-id=\"3323867\" data-linked=\"Synchrony Financial down 1% after earnings beat\" data-tweet=\"$SYF - Synchrony Financial down 1% after earnings beat https://seekingalpha.com/news/3323867-synchrony-financial-down-1-after-earnings-beat?source=tweet\" data-url=\"https://seekingalpha.com/news/3323867-synchrony-financial-down-1-after-earnings-beat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323864\" data-ts=\"1516371008\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HMNY\" target=\"_blank\">HMNY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323864-moviepass-launches-film-investment-subsidiary\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MoviePass launches film investment subsidiary</a></h4><ul><li>        Helios and Matheson Analytics (NASDAQ:<a href='https://seekingalpha.com/symbol/HMNY' title='Helios and Matheson Analytics, Inc.'>HMNY</a>) <a href=\"https://www.businesswire.com/news/home/20180119005325/en/MoviePassTM-Unveils-Strategy-Invest-Film%C2%A0at-Sundance-Film\" target=\"_blank\">announces</a> that its majority-owned subsidiary MoviePass has launched a wholly-owned subsidiary, MoviePass Ventures.</li><li>               Ventures was founded to &ldquo;co-acquire films with film distributors.&rdquo;</li><li>               MoviePass currently purchases about 3% of domestic box office but will purchase more than 10% of a particular movie&rsquo;s box office using a series of levers to impact a consumer&rsquo;s selection of an indie film.&nbsp;</li><li>               Example titles having impacted at least 10% box office performance: The Post, Call Me By Your Name, and The Shape of Water. &nbsp;&nbsp;</li><li>               Helios and Matheson shares are&nbsp;<font color='green'>up 1.4%</font>&nbsp;premarket.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3322936-moviepass-appoints-first-cmo\" target=\"_blank\">MoviePass appoints first CMO</a> (Jan. 16)</li></ul><div class=\"tiny-share-widget\" data-id=\"3323864\" data-linked=\"MoviePass launches film investment subsidiary\" data-tweet=\"$HMNY - MoviePass launches film investment subsidiary https://seekingalpha.com/news/3323864-moviepass-launches-film-investment-subsidiary?source=tweet\" data-url=\"https://seekingalpha.com/news/3323864-moviepass-launches-film-investment-subsidiary\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:10 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323862\" data-ts=\"1516370923\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323862-premarket-losers-of-9-05-1-19-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am (1/19/2018)</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/PAVM' title='PAVmed Inc.'>PAVM</a>&nbsp;<font color='red'>-29%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3323834-pavmed-readies-stock-offering-shares-21-percent-premarket\" target=\"_blank\">pricing</a> common stock offering.</li><li><a href='https://seekingalpha.com/symbol/HTGM' title='HTG Molecular Diagnostics'>HTGM</a>&nbsp;<font color='red'>-9%</font>&nbsp;on&nbsp;<a href=\"https://seekingalpha.com/news/3323780-htg-molecular-diagnostics-minus-4-percent-pricing-offering\" target=\"_blank\">pricing</a>&nbsp;common stock offering.</li><li><a href='https://seekingalpha.com/symbol/GENE' title='GENETIC TECHNOLOGIES LTD'>GENE</a> <font color='red'>-6%</font>.</li><li><a href='https://seekingalpha.com/symbol/GNC' title='GNC Holdings, Inc.'>GNC</a> <font color='red'>-6%</font>.</li><li><a href='https://seekingalpha.com/symbol/TUSK' title='Mammoth Energy Services'>TUSK</a> <font color='red'>-5%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3323862\" data-linked=\"Premarket Losers as of 9:05 am (1/19/2018)\" data-tweet=\"$PAVM $HTGM $GENE - Premarket Losers as of 9:05 am (1/19/2018) https://seekingalpha.com/news/3323862-premarket-losers-of-9-05-1-19-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3323862-premarket-losers-of-9-05-1-19-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323861\" data-ts=\"1516370811\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PLAY\" target=\"_blank\">PLAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323861-dave-busters-be-worth-61-in-buyout-suntrust\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dave &amp; Buster&#39;s could be worth $61 in buyout - SunTrust</a></h4><ul><li>Roughed-up Dave &amp; Buster's (NASDAQ:<a href='https://seekingalpha.com/symbol/PLAY' title='Dave & Buster&#39;s Entertainment, Inc.'>PLAY</a>) is getting a small premarket bounce after SunTrust says the stock could be worth $61 per share in an LBO. This was a $70-plus stock a few months back.</li><li>No other details are yet available.</li><li>Shares&nbsp;<font color='green'>+2.1%</font>&nbsp;to $47</li><li>Previously: <a href=\"https://seekingalpha.com/news/3321608-weak-guidance-sends-dave-and-busters-reeling\" target=\"_blank\">Weak guidance sends Dave &amp; Buster's reeling</a> (Jan. 8)</li></ul><div class=\"tiny-share-widget\" data-id=\"3323861\" data-linked=\"Dave &amp; Buster&#39;s could be worth $61 in buyout - SunTrust\" data-tweet=\"$PLAY - Dave &amp; Buster&#39;s could be worth $61 in buyout - SunTrust https://seekingalpha.com/news/3323861-dave-busters-be-worth-61-in-buyout-suntrust?source=tweet\" data-url=\"https://seekingalpha.com/news/3323861-dave-busters-be-worth-61-in-buyout-suntrust\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:06 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323853\" data-ts=\"1516369855\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/URGN\" target=\"_blank\">URGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323853-urogen-prices-stock-offering-41-shares-off-1-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">UroGen prices stock offering at $41; shares off 1% premarket</a></h4><ul><li>UroGen Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/URGN' title='UroGen Pharma'>URGN</a>) <a href=\"https://seekingalpha.com/pr/17051014-urogen-pharma-announces-pricing-public-offering-ordinary-shares\" target=\"_blank\">prices </a>its public offering of 1,463,414 shares of common stock at $41 per share yielding gross proceeds of ~$60M. Underwriters over-allotment is an additional 219,512 shares. Closing date is January 23.</li><li>Yesterday's close was $42.46. Shares are down&nbsp;<font color='red'>1%</font>&nbsp;premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3323853\" data-linked=\"UroGen prices stock offering at $41; shares off 1% premarket\" data-tweet=\"$URGN - UroGen prices stock offering at $41; shares off 1% premarket https://seekingalpha.com/news/3323853-urogen-prices-stock-offering-41-shares-off-1-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3323853-urogen-prices-stock-offering-41-shares-off-1-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:50 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323848\" data-ts=\"1516368721\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IBM\" target=\"_blank\">IBM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323848-ibm-q4-earnings-call-fy18-guidance-tax-forecast-and-margin-erosion\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">IBM Q4 earnings call: FY18 guidance, tax forecast, and margin erosion</a></h4><ul><li>           IBM (NYSE:<a href='https://seekingalpha.com/symbol/IBM' title='International Business Machines Corporation'>IBM</a>) held its Q4 earnings call (<a href=\"https://seekingalpha.com/article/4138552-international-business-machines-ibm-q4-2017-results-earnings-call-transcript?part=single\" target=\"_blank\">transcript</a>) aftermarket yesterday and included FY18 guidance and more details on the quarterly report. </li><li> FY18 guidance: Operating EPS flat on the year to &ldquo;at least $13.80&rdquo; (consensus: $13.92). FCF expected at about $12B. IBM expects a headwind from cash tax payments to the tune of about $600M year-to-year. </li><li> Tax: 2018 operating tax rate of 14% to 18% (before any discretes) incorporates the new tax law and is a four-point headwind year-to-year. Management reminds investors that the company took discrete items in Q1 and Q2 last year, which brought the operating tax rate down to 7% for the year. </li><li>           Q4 margins: Bernstein analyst Toni Sacconaghi mentions during the call that GBS and Tech Services margin erosion was &ldquo;the worst we&rsquo;ve seen in history on a pretax basis.&rdquo;<br />Operating gross margin was down a little over a point on the year and about 0.5 points behind guidance due to mix and yield delay in the Services business. Global Business Services margins were down 2.1 points to 24.8%, Cognitive Solutions down 3.5 points to 79.2%, Tech Services &amp; Cloud Platforms down 2 points to 40.9%, and Systems down 1.2 points to 55.7%.  </li><li> <a href=\"https://seekingalpha.com/pr/17050824-ibm-reports-2017-fourth-quarter-full-year-results\" target=\"_blank\">Earnings press release.</a> </li><li> IBM shares are&nbsp;<font color='red'>down 3.2%</font>&nbsp;premarket. &nbsp;&nbsp; </li><li>Previously: <a href=\"https://seekingalpha.com/news/3323691-international-business-machines-beats-0_01-beats-revenue\" target=\"_blank\">International Business Machines beats by $0.01, beats on revenue</a> (Jan. 18)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3323747-ibm-minus-4_4-percent-despite-beating-q4-estimates-posting-first-revenue-growth-nearly-6\" target=\"_blank\">IBM -4.4% despite beating Q4 estimates, posting first revenue growth in nearly 6 years</a> (Jan. 18)</li></ul><div class=\"tiny-share-widget\" data-id=\"3323848\" data-linked=\"IBM Q4 earnings call: FY18 guidance, tax forecast, and margin erosion\" data-tweet=\"$IBM - IBM Q4 earnings call: FY18 guidance, tax forecast, and margin erosion https://seekingalpha.com/news/3323848-ibm-q4-earnings-call-fy18-guidance-tax-forecast-and-margin-erosion?source=tweet\" data-url=\"https://seekingalpha.com/news/3323848-ibm-q4-earnings-call-fy18-guidance-tax-forecast-and-margin-erosion\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:32 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>47&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323846\" data-ts=\"1516368639\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PM\" target=\"_blank\">PM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323846-philip-morris-altria-up-1-on-upgrades\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Philip Morris, Altria up more than 1% on upgrades</a></h4><ul><li>Analyst Owen Bennett is bullish on the tobacco sector, seeing total returns over the next 12 months of 15% topping that of consumer staples by 500 basis points.</li><li>Keys: Reduced risk product &#40;RRP&#41; segment development, possible M&amp;A, increasing bond yields, and forex changes being a tailwind after years of headwinds.</li><li>He upgrades Philip Morris (NYSE:<a href='https://seekingalpha.com/symbol/PM' title='Philip Morris International Inc.'>PM</a>) to Buy, with next week's Tobacco Products Scientific Advisory Committee review being a possible immediate catalyst.</li><li>He also upgrades Altria (NYSE:<a href='https://seekingalpha.com/symbol/MO' title='Altria Group, Inc.'>MO</a>) to Buy, betting the company can halt the recent market share decline for Marlboro.</li><li>British American Tobacco (NYSEMKT:<a href='https://seekingalpha.com/symbol/BTI' title='British American Tobacco p.l.c. &#40;American Depository Receipts&#41;'>BTI</a>) remains his Top Pick.</li><li>PM and MO are&nbsp;<font color='green'>up 1.1%</font>&nbsp;premarket; BTI&nbsp;<font color='green'>+0.6%</font></li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3323846\" data-linked=\"Philip Morris, Altria up more than 1% on upgrades\" data-tweet=\"$PM $PM $MO - Philip Morris, Altria up more than 1% on upgrades https://seekingalpha.com/news/3323846-philip-morris-altria-up-1-on-upgrades?source=tweet\" data-url=\"https://seekingalpha.com/news/3323846-philip-morris-altria-up-1-on-upgrades\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>70&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323845\" data-ts=\"1516368448\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HTBX\" target=\"_blank\">HTBX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323845-heat-biologics-to-reverse-split-shares-1-10-today-shares-down-8-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Heat Biologics to reverse split shares 1:10 today; shares down 8% premarket</a></h4><ul><li>Aimed at regaining compliance with Nasdaq's listing requirement of a $1 minimum bid price, Heat Biologics (NASDAQ:<a href='https://seekingalpha.com/symbol/HTBX' title='Heat Biologics, Inc.'>HTBX</a>) will execute a <a href=\"https://www.sec.gov/Archives/edgar/data/1476963/000155335018000059/htbx_8k.htm\" target=\"_blank\">1:10 reverse split</a> of it common stock at 11:00 pm ET today. Post-split trading will commence on Monday, January 22.</li><li>Shares are down&nbsp;<font color='red'>8%</font>&nbsp;premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3323845\" data-linked=\"Heat Biologics to reverse split shares 1:10 today; shares down 8% premarket\" data-tweet=\"$HTBX - Heat Biologics to reverse split shares 1:10 today; shares down 8% premarket https://seekingalpha.com/news/3323845-heat-biologics-to-reverse-split-shares-1-10-today-shares-down-8-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3323845-heat-biologics-to-reverse-split-shares-1-10-today-shares-down-8-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323844\" data-ts=\"1516368316\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OSTK\" target=\"_blank\">OSTK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323844-ny-post-retailers-consider-deals-for-boxed-com-kroger-eyeing-overstock\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NY Post: Retailers consider deals for Boxed.com, Kroger eyeing Overstock</a></h4><ul>     <li>Overstock.com (NASDAQ:<a href='https://seekingalpha.com/symbol/OSTK' title='Overstock.com, Inc.'>OSTK</a>)&nbsp;<font color='green'>+4%</font> premarket following a <em>New York Post</em> report that General Mills (NYSE:<a href='https://seekingalpha.com/symbol/GIS' title='General Mills, Inc.'>GIS</a>) and Bed Bath &amp; Beyond (NASDAQ:<a href='https://seekingalpha.com/symbol/BBBY' title='Bed Bath & Beyond Inc.'>BBBY</a>) are <a href=\"https://nypost.com/2018/01/19/retailers-consider-investing-in-online-costco-for-millennials/\" target=\"_blank\">weighing investments in Boxed.com</a>.</li>     <li>The tech startup, whose network of distribution centers provides 24-hour delivery to much of the U.S. - also reportedly is in advanced negotiations to be sold to supermarket giant Kroger (NYSE:<a href='https://seekingalpha.com/symbol/KR' title='Kroger Co.'>KR</a>) for as much as $500M, although Costco (NASDAQ:<a href='https://seekingalpha.com/symbol/COST' title='Costco Wholesale Corporation'>COST</a>) apparently is not interested.</li><li>KR also may be considering a deal with OSTK, according to the <em>Post</em> report; CEO Patrick Byrne said last month that he plans to  sell or reorganize the e-commerce business to focus on blockchain  technology.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3323844\" data-linked=\"NY Post: Retailers consider deals for Boxed.com, Kroger eyeing Overstock\" data-tweet=\"$OSTK $OSTK $GIS - NY Post: Retailers consider deals for Boxed.com, Kroger eyeing Overstock https://seekingalpha.com/news/3323844-ny-post-retailers-consider-deals-for-boxed-com-kroger-eyeing-overstock?source=tweet\" data-url=\"https://seekingalpha.com/news/3323844-ny-post-retailers-consider-deals-for-boxed-com-kroger-eyeing-overstock\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:25 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323843\" data-ts=\"1516368298\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALBO\" target=\"_blank\">ALBO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323843-albireo-to-receive-55m-on-elobixibat-approval-in-japan\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Albireo to receive more than $55M on elobixibat approval in Japan</a></h4><ul> <li>Albireo Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/ALBO' title='Albireo Pharma, Inc.'>ALBO</a>) <a href=\"https://seekingalpha.com/pr/17051151-albireo-receive-55-million-1-nondilutive-cash-payments\" target=\"_blank\">announces</a>&nbsp;that Japan&rsquo;s&nbsp;Ministry of Health, Labor and Welfare has approved the new drug application for IBAT inhibitor&nbsp;<a href=\"http://www.albireopharma.com/programs/elobixibat\" target=\"_blank\">elobixibat</a> for the treatment of chronic constipation in&nbsp;Japan.</li>    <li>Under the terms of a license agreement, Albireo subsidiary Elobix AB will receive payments of more than $55M from EA Pharma Co. and HealthCare Royalty Partners.</li>      <li>Elobixibat will be marketed&nbsp;under the trade name GOOFICE.</li><li><strong>Update</strong>: Shares are up&nbsp;<font color='green'>14%</font>&nbsp;in the last hour of trading.</li>    </ul><div class=\"tiny-share-widget\" data-id=\"3323843\" data-linked=\"Albireo to receive more than $55M on elobixibat approval in Japan\" data-tweet=\"$ALBO - Albireo to receive more than $55M on elobixibat approval in Japan https://seekingalpha.com/news/3323843-albireo-to-receive-55m-on-elobixibat-approval-in-japan?source=tweet\" data-url=\"https://seekingalpha.com/news/3323843-albireo-to-receive-55m-on-elobixibat-approval-in-japan\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:24 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323842\" data-ts=\"1516367908\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NXPI\" target=\"_blank\">NXPI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323842-elliott-boosts-stake-in-nxp-says-qualcomm-bid-not-even-in-right-zip-code\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Elliott boosts stake in NXP, says Qualcomm bid &#39;not even in the right zip code&#39;</a></h4><ul><li>Elliott Advisors says it now holds a 6.6% stake in NXP Semi (NASDAQ:<a href='https://seekingalpha.com/symbol/NXPI' title='NXP Semiconductors'>NXPI</a>).</li><li>In a letter to NXP shareholders, firm says NXP \"is of significant strategic importance to Qualcomm,\" and that an acquisition \"will deliver substantial value to Qualcomm shareholders at prices meaningfully higher than Elliott&rsquo;s own assessment of standalone intrinsic value of $135 per share.\" QCOM's current offer is $110/share.</li><li>Read the full letter <a href=\"http://fairvaluefornxp.com/media/1255/jan19_nxp_shareholderletter.pdf\" target=\"_blank\">here</a>&nbsp;(.pdf). Elliott also published a UBS analysis of NXPI's value, found <a href=\"http://fairvaluefornxp.com/media/1258/jan19_nxp_ubsfinancialanalysis.pdf\" target=\"_blank\">here</a> (.pdf).</li><li>NXPI&nbsp;<font color='green'>+0.4%</font>&nbsp;premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3323842\" data-linked=\"Elliott boosts stake in NXP, says Qualcomm bid &#39;not even in the right zip code&#39;\" data-tweet=\"$NXPI $NXPI $QCOM - Elliott boosts stake in NXP, says Qualcomm bid &#39;not even in the right zip code&#39; https://seekingalpha.com/news/3323842-elliott-boosts-stake-in-nxp-says-qualcomm-bid-not-even-in-right-zip-code?source=tweet\" data-url=\"https://seekingalpha.com/news/3323842-elliott-boosts-stake-in-nxp-says-qualcomm-bid-not-even-in-right-zip-code\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>82&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323840\" data-ts=\"1516367181\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SQ\" target=\"_blank\">SQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323840-square-another-amazon-google-shares-up-3_8\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Square another Amazon or Google? Shares up 3.8%</a></h4><ul><li>Like Amazon or Google in their early days, it's tough to put a price on Square (NYSE:<a href='https://seekingalpha.com/symbol/SQ' title='Square, Inc.'>SQ</a>) using traditional valuation metrics, says Nomura's Dan Dolev, lifting his price target from $48 to a Street-high $64. That would be&nbsp;<font color='green'>60% upside</font>&nbsp;from yesterday's close.</li><li>Better to use bottom-up discounted cash flow, which considers the shift to big merchants, accelerating share gains, increasing penetration of higher-priced transaction types, and high-margin services like Square Capital and payroll.</li><li>Shares&nbsp;<font color='green'>+3.8%</font>&nbsp;premarket to $41.80</li><li>Source: Bloomberg's Lily Katz</li></ul><div class=\"tiny-share-widget\" data-id=\"3323840\" data-linked=\"Square another Amazon or Google? Shares up 3.8%\" data-tweet=\"$SQ - Square another Amazon or Google? Shares up 3.8% https://seekingalpha.com/news/3323840-square-another-amazon-google-shares-up-3_8?source=tweet\" data-url=\"https://seekingalpha.com/news/3323840-square-another-amazon-google-shares-up-3_8\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:06 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>54&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323836\" data-ts=\"1516366804\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WDC\" target=\"_blank\">WDC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323836-macquarie-initiates-western-digital\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Macquarie initiates Western Digital</a></h4><ul><li>        Macquarie <a href=\"https://www.streetinsider.com/Analyst+Comments/Macquarie+Starts+Western+Digital+Corp.+%28WDC%29+at+Neutral/13701137.html\" target=\"_blank\">initiates</a> Western Digital (NYSE:<a href='https://seekingalpha.com/symbol/WDC' title='Western Digital Corporation'>WDC</a>) at Neutral with a $90 price target, which is 4% higher than yesterday&rsquo;s closing price.</li><li>               Analyst Srini Pajjuri says the firm thinks Western Digital&rsquo;s &ldquo;top line has the potential to grow at a mid-single-digit rate longer-term as NAND growth should more than offset HDD declines.&nbsp;</li><li>               Western Digital shares are&nbsp;<font color='red'>down 0.2%</font>&nbsp;premarket. &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3323836\" data-linked=\"Macquarie initiates Western Digital\" data-tweet=\"$WDC - Macquarie initiates Western Digital https://seekingalpha.com/news/3323836-macquarie-initiates-western-digital?source=tweet\" data-url=\"https://seekingalpha.com/news/3323836-macquarie-initiates-western-digital\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323834\" data-ts=\"1516366603\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PAVM\" target=\"_blank\">PAVM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323834-pavmed-readies-stock-offering-shares-down-21-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PAVmed readies stock offering; shares down 21% premarket</a></h4><ul><li>Thinly traded nano cap PAVmed (NASDAQ:<a href='https://seekingalpha.com/symbol/PAVM' title='PAVmed Inc.'>PAVM</a>) slumps&nbsp;<font color='red'>21%</font>&nbsp;premarket, albeit on only 300 shares, on the heels of its filing of a <a href=\"https://www.sec.gov/Archives/edgar/data/1624326/000149315218000742/form424b5.htm\" target=\"_blank\">prospectus supplemen</a>t for a planned public offering of common stock. Price and volume have yet to be announced.</li><li><strong>Update</strong>: The <a href=\"https://seekingalpha.com/pr/17051187-pavmed-announces-pricing-firm-commitment-common-stock-offering\" target=\"_blank\">offering </a>is 2,415,278 common shares at $1.80 per share. Underwriters over-allotment is an additional 362,292 shares. Net proceeds should be ~$3.9M. Closing date is January 23. Yesterday's close was $2.54.</li></ul><div class=\"tiny-share-widget\" data-id=\"3323834\" data-linked=\"PAVmed readies stock offering; shares down 21% premarket\" data-tweet=\"$PAVM - PAVmed readies stock offering; shares down 21% premarket https://seekingalpha.com/news/3323834-pavmed-readies-stock-offering-shares-down-21-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3323834-pavmed-readies-stock-offering-shares-down-21-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:56 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323831\" data-ts=\"1516366347\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZG\" target=\"_blank\">ZG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323831-stifel-resumes-zillow-13-downside\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stifel resumes Zillow with a 13% downside</a></h4><ul><li>           Stifel <a href=\"https://www.streetinsider.com/Analyst+Comments/UPDATE%3A+Stifel+Resumes+Zillow+Group+%28ZG%29+at+Hold/13700253.html\" target=\"_blank\">resumes coverage</a> of Zillow (NASDAQ:<a href='https://seekingalpha.com/symbol/ZG' title='Zillow Group, Inc.'>ZG</a>) with a Hold rating and $38 price target, which is 13% below yesterday&rsquo;s closing price. </li><li> Analyst John Egbert calls Zillow a category leader in online real estate and a developer of innovative digital and marketing solutions for real estate professionals. </li><li> But Egbert notes that Zillow recently shifted to auction-based pricing for lead sales to agents, which could cause bumps in seasonally slow Q4. </li><li>           Other potential headwinds include tight housing supply and rising interest rates. &nbsp; </li><li>           Zillow shares are&nbsp;<font color='red'>down 0.1%</font>&nbsp;premarket.&nbsp; </li></ul><div class=\"tiny-share-widget\" data-id=\"3323831\" data-linked=\"Stifel resumes Zillow with a 13% downside\" data-tweet=\"$ZG - Stifel resumes Zillow with a 13% downside https://seekingalpha.com/news/3323831-stifel-resumes-zillow-13-downside?source=tweet\" data-url=\"https://seekingalpha.com/news/3323831-stifel-resumes-zillow-13-downside\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:52 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323827\" data-ts=\"1516365532\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APPN\" target=\"_blank\">APPN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323827-william-blair-downgrades-appian\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">William Blair downgrades Appian</a></h4><ul><li>        William Blair <a href=\"https://www.streetinsider.com/Analyst+Comments/William+Blair+Downgrades+Appian+Corp.+%28APPN%29+to+Market+Perform/13701282.html\" target=\"_blank\">downgrades</a> Appian (NASDAQ:<a href='https://seekingalpha.com/symbol/APPN' title='Appian Corp.'>APPN</a>) from Outperform to Market Perform.</li><li>                  Latest analyst <a href=\"https://markets.ft.com/data/equities/tearsheet/forecasts?s=APPN:NMQ\" target=\"_blank\">recommendations</a>: 1 Buy, 4 Hold, and 3 Underperform.    </li><li>               Median price target: $23.50.&nbsp;</li><li>               Appian shares are&nbsp;<font color='red'>down 1.1%</font>&nbsp;premarket.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3323586-appian-minus-6_9-percent-goldman-downgrade\" target=\"_blank\">Appian -6.9% on Goldman downgrade</a> (Jan. 18)</li></ul><div class=\"tiny-share-widget\" data-id=\"3323827\" data-linked=\"William Blair downgrades Appian\" data-tweet=\"$APPN - William Blair downgrades Appian https://seekingalpha.com/news/3323827-william-blair-downgrades-appian?source=tweet\" data-url=\"https://seekingalpha.com/news/3323827-william-blair-downgrades-appian\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:38 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323826\" data-ts=\"1516365057\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACOR\" target=\"_blank\">ACOR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323826-potential-suitors-eyeing-acorda-therapeutics-shares-ahead-9-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Potential suitors eyeing Acorda Therapeutics, shares ahead 9% premarket</a></h4><ul><li>Acorda Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ACOR' title='Acorda Therapeutics, Inc.'>ACOR</a>) is up&nbsp;<font color='green'>9%</font>&nbsp;premarket on light volume on the heels of <a href=\"https://endpts.com/biogen-ucb-step-up-to-kick-the-tires-at-acorda-as-buyout-buzz-grows-report/\" target=\"_blank\">reports </a>that Biogen (NASDAQ:<a href='https://seekingalpha.com/symbol/BIIB' title='Biogen Inc.'>BIIB</a>), UCB S.A. (<a href='https://seekingalpha.com/symbol/UCBJF' title='UCB S.A.'>OTCPK:UCBJF</a>) and possibly certain Asian drugmakers are mulling bids.</li><li>The company has been facing generic competition for top seller Ampyra (dalfampridine) since the USPTO invalidated several key patents. In Q3, the MS med accounted for almost 99% of its Q3 product revenue of $134.4M ($132.6M). Last month, the company resubmitted its U.S. marketing application for INBRIJA for the treatment of OFF periods in Parkinson's disease patients.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3321495-acorda-12-percent-potential-sale\" target=\"_blank\">Acorda up 12% on potential sale</a> (Jan. 5)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3316892-acorda-refiles-u-s-marketing-application-parkinsons-med-inbrija-shares-5-percent-premarket\" target=\"_blank\">Acorda refiles U.S. marketing application for Parkinson's med Inbrija; shares up 5% premarket</a> (Dec. 7, 2017)</li></ul><div class=\"tiny-share-widget\" data-id=\"3323826\" data-linked=\"Potential suitors eyeing Acorda Therapeutics, shares ahead 9% premarket\" data-tweet=\"$ACOR $ACOR $BIIB - Potential suitors eyeing Acorda Therapeutics, shares ahead 9% premarket https://seekingalpha.com/news/3323826-potential-suitors-eyeing-acorda-therapeutics-shares-ahead-9-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3323826-potential-suitors-eyeing-acorda-therapeutics-shares-ahead-9-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:30 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323824\" data-ts=\"1516364603\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IPCI\" target=\"_blank\">IPCI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323824-premarket-analyst-action-healthcare\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket analyst action - healthcare</a></h4><ul><li>Intellipharmaceutics (NASDAQ:<a href='https://seekingalpha.com/symbol/IPCI' title='IntelliPharmaCeutics International Inc'>IPCI</a>) initiated with Buy rating and $2.50 (213% upside) price target by H.C. Wainwright.</li><li>PLx Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/PLXP' title='PLx Pharma'>PLXP</a>) initiated with Buy rating and $14 (130% upside) price target by Janney.</li><li>Vanda Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/VNDA' title='Vanda Pharmaceuticals Inc.'>VNDA</a>) initiated with Buy rating and $20 (40% upside) price target by Seaport Global Securities.</li><li>Cara Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/CARA' title='Cara Therapeutics Inc.'>CARA</a>) initiated with Buy rating and $27 (117% upside) price target by Seaport.</li><li>Pacira Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/PCRX' title='Pacira Pharmaceuticals, Inc.'>PCRX</a>) initiated with Buy rating and $50 (28% upside) price target by Seaport.</li><li>Corbus Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/CRBP' title='Corbus Pharmaceuticals Holdings, Inc.'>CRBP</a>) initiated with Outperform rating and $24 (202% upside) price target by Raymond James.</li><li>ICON plc (NASDAQ:<a href='https://seekingalpha.com/symbol/ICLR' title='Icon PLC'>ICLR</a>) initiated with Outperform rating and $126 (13% upside) price target by Evercore ISI.</li><li>Alnylam Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ALNY' title='Alnylam Pharmaceuticals, Inc.'>ALNY</a>) an Out of the Gate 2018 Pick at B. Riley FBR with a $205 (65% upside) price target citing expected positive FDA decision on patisiran in hATTR in July and expected positive Phase 3 data in porphyria (ENVISION study).</li><li>Athenahealth (NASDAQ:<a href='https://seekingalpha.com/symbol/ATHN' title='athenahealth, Inc.'>ATHN</a>) resumed with Neutral rating and $140 (11% upside) price target by Evercore ISI.</li><li>Cerner (NASDAQ:<a href='https://seekingalpha.com/symbol/CERN' title='Cerner Corporation'>CERN</a>) resumed with Neutral rating and $77 (11% upside) price target by Evercore ISI.</li><li>Charles River Labs (NYSE:<a href='https://seekingalpha.com/symbol/CRL' title='Charles River Laboratories International, Inc.'>CRL</a>) resumed with Neutral rating and $117 (9% upside) price target by Evercore ISI.</li><li>Allscripts (NASDAQ:<a href='https://seekingalpha.com/symbol/MDRX' title='Allscripts Healthcare Solutions, Inc.'>MDRX</a>) resumed with Outperform rating and $17.50 (17% upside) price target by Evercore ISI.</li><li>Premier (NASDAQ:<a href='https://seekingalpha.com/symbol/PINC' title='Premier, Inc.'>PINC</a>) resumed with Neutral rating and $33.50 (4% upside) price target by Evercore ISI.</li><li>Becton, Dickinson &amp; Company (NYSE:<a href='https://seekingalpha.com/symbol/BDX' title='Becton, Dickinson and Company'>BDX</a>) resumed with Buy rating and $260 (12% upside) price target by BofA/Merrill Lynch.</li><li>Neovasc (NASDAQ:<a href='https://seekingalpha.com/symbol/NVCN' title='Neovasc Inc.'>NVCN</a>) resumed with Buy rating by Canaccord Genuity.</li><li>Ocular Therapeutix (NASDAQ:<a href='https://seekingalpha.com/symbol/OCUL' title='Ocular Therapeutix'>OCUL</a>) upgraded to Buy by BTIG Research.</li><li>Atara Biotherapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ATRA' title='Atara Biotherapeutics'>ATRA</a>) price target raised to $70 (155% upside) from $47 at Canaccord Genuity. Shares up&nbsp;<font color='green'>6%</font>&nbsp;premarket on light volume.</li><li>Sientra (NASDAQ:<a href='https://seekingalpha.com/symbol/SIEN' title='Sientra'>SIEN</a>) upgraded to Buy with a $14 (40% upside) price target by Stifel.</li><li>Hologic (NASDAQ:<a href='https://seekingalpha.com/symbol/HOLX' title='Hologic, Inc.'>HOLX</a>) downgraded to Hold by Deutsche Bank.</li><li>Align Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/ALGN' title='Align Technology, Inc.'>ALGN</a>) downgraded to Equal Weight by Stephens.</li></ul><div class=\"tiny-share-widget\" data-id=\"3323824\" data-linked=\"Premarket analyst action - healthcare\" data-tweet=\"$IPCI $IPCI $PLXP - Premarket analyst action - healthcare https://seekingalpha.com/news/3323824-premarket-analyst-action-healthcare?source=tweet\" data-url=\"https://seekingalpha.com/news/3323824-premarket-analyst-action-healthcare\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323823\" data-ts=\"1516364584\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SWCH\" target=\"_blank\">SWCH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323823-cowen-initiates-switch-12-downside\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cowen initiates Switch with 12% downside</a></h4><ul><li>           Cowen initiates Switch (NYSE:<a href='https://seekingalpha.com/symbol/SWCH' title='Switch, Inc.'>SWCH</a>) at Underperform with a $15 price target, which is nearly 12% lower than yesterday&rsquo;s close. </li><li>           Latest analyst <a href=\"https://markets.ft.com/data/equities/tearsheet/forecasts?s=SWCH:NYQ\" target=\"_blank\">recommendations</a>: 2 Buy, 3 Outperform, and 5 Hold.  </li><li> Median price target: $20. </li><li> Switch shares are&nbsp;<font color='red'>down 1.6%</font>&nbsp;premarket to $16.75. &nbsp;&nbsp; </li></ul><div class=\"tiny-share-widget\" data-id=\"3323823\" data-linked=\"Cowen initiates Switch with 12% downside\" data-tweet=\"$SWCH - Cowen initiates Switch with 12% downside https://seekingalpha.com/news/3323823-cowen-initiates-switch-12-downside?source=tweet\" data-url=\"https://seekingalpha.com/news/3323823-cowen-initiates-switch-12-downside\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323814\" data-ts=\"1516362833\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OBLN\" target=\"_blank\">OBLN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323814-obalon-prices-stock-offering-5_50-shares-down-6-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Obalon prices stock offering at $5.50; shares down 6% premarket</a></h4><ul><li>Obalon Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/OBLN' title='Obalon Therapeutics'>OBLN</a>) <a href=\"https://seekingalpha.com/pr/17051044-obalon-therapeutics-prices-public-offering-common-stock\" target=\"_blank\">prices </a>its public offering of 5,454,545 shares of common stock at $5.50 per share. Underwriters over-allotment is an additional 818,181 shares. Closing date is January 23.</li><li>Shares are off&nbsp;<font color='red'>6%</font>&nbsp;premarket on light volume. Yesterday's close was $6.14.</li></ul><div class=\"tiny-share-widget\" data-id=\"3323814\" data-linked=\"Obalon prices stock offering at $5.50; shares down 6% premarket\" data-tweet=\"$OBLN - Obalon prices stock offering at $5.50; shares down 6% premarket https://seekingalpha.com/news/3323814-obalon-prices-stock-offering-5_50-shares-down-6-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3323814-obalon-prices-stock-offering-5_50-shares-down-6-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323811\" data-ts=\"1516362601\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGIO\" target=\"_blank\">AGIO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323811-agios-pharma-prices-stock-offering-67\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Agios Pharma prices stock offering at $67</a></h4><ul><li>Agios Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/AGIO' title='Agios Pharmaceuticals, Inc.'>AGIO</a>) <a href=\"https://seekingalpha.com/pr/17051037-agios-announces-pricing-475-million-public-offering-common-stock\" target=\"_blank\">prices </a>its public offering of 7,089,553 shares of common stock at $67 per share. Underwriters over-allotment is an additional ~1.06M shares. Closing date is January 23. Gross proceeds should be ~$475M.</li><li>Shares are up a fraction premarket. Yesterday's close was $68.15.</li></ul><div class=\"tiny-share-widget\" data-id=\"3323811\" data-linked=\"Agios Pharma prices stock offering at $67\" data-tweet=\"$AGIO - Agios Pharma prices stock offering at $67 https://seekingalpha.com/news/3323811-agios-pharma-prices-stock-offering-67?source=tweet\" data-url=\"https://seekingalpha.com/news/3323811-agios-pharma-prices-stock-offering-67\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:50 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323810\" data-ts=\"1516362352\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AZN\" target=\"_blank\">AZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323810-astrazenecas-lynparza-okd-in-japan-for-ovarian-cancer-shares-up-1-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AstraZeneca&#39;s Lynparza OK&#39;d in Japan for ovarian cancer; shares up 1% premarket</a></h4><ul><li>AstraZeneca (NYSE:<a href='https://seekingalpha.com/symbol/AZN' title='AstraZeneca Group plc'>AZN</a>) and oncology collaboration partner Merck (NYSE:<a href='https://seekingalpha.com/symbol/MRK' title='Merck & Co Inc.'>MRK</a>) <a href=\"https://seekingalpha.com/pr/17051092-lynparza-olaparib-receives-approval-japan-treatment-advanced-ovarian-cancer\" target=\"_blank\">announce</a> that the Japanese Ministry of Health, Labour and Welfare has approved LYNPARZA (olaparib) as maintenance therapy for patients with platinum-sensitive relapsed ovarian cancer, regardless of BRCA mutation status, who responded to their last cycle of platinum-based chemo.</li><li>LYNPARZA is the first PARP inhibitor approved in Japan.</li><li>AZN is up&nbsp;<font color='green'>1%</font>&nbsp;premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3323810\" data-linked=\"AstraZeneca&#39;s Lynparza OK&#39;d in Japan for ovarian cancer; shares up 1% premarket\" data-tweet=\"$AZN $AZN $MRK - AstraZeneca&#39;s Lynparza OK&#39;d in Japan for ovarian cancer; shares up 1% premarket https://seekingalpha.com/news/3323810-astrazenecas-lynparza-okd-in-japan-for-ovarian-cancer-shares-up-1-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3323810-astrazenecas-lynparza-okd-in-japan-for-ovarian-cancer-shares-up-1-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:45 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323804\" data-ts=\"1516361453\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SYF\" target=\"_blank\">SYF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323804-synchrony-financial-beats-0_07-misses-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Synchrony Financial beats by $0.07, misses on revenue</a></h4><ul><li>Synchrony Financial (NYSE:<a href='https://seekingalpha.com/symbol/SYF' title='Synchrony Financial'>SYF</a>): Q4 EPS of $0.70 <font color='green'>beats by $0.07</font>.</li><li>Revenue of $3.92B (+8.0% Y/Y) <font color='red'>misses by $40M</font>.</li><li>Shares <font color='green'>+3.2%</font> PM.</li><li><a href='https://seekingalpha.com/pr/17051097-synchrony-financial-reports-fourth-quarter-net-earnings-385-million-0_49-per-diluted-share'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3323804\" data-linked=\"Synchrony Financial beats by $0.07, misses on revenue\" data-tweet=\"$SYF - Synchrony Financial beats by $0.07, misses on revenue https://seekingalpha.com/news/3323804-synchrony-financial-beats-0_07-misses-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3323804-synchrony-financial-beats-0_07-misses-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:30 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323795\" data-ts=\"1516358239\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVDA\" target=\"_blank\">NVDA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323795-bofa-hikes-nvidia-price-target-estimates\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BofA hikes Nvidia price target, estimates</a></h4><ul><li>BofA raises its price target for Nvidia (NASDAQ:<a href='https://seekingalpha.com/symbol/NVDA' title='NVIDIA Corporation'>NVDA</a>) to $275 from $251, citing:</li><li>Analysis of Dec. online gamer data.</li><li>Upside in HPC (high-performance computing) <a href=\"https://seekingalpha.com/news/3323673\" target=\"_blank\">highlighted by TSMC</a> in its Q4 report.</li><li>Continued strength in crypto (Ethereum) and Nintendo Switch sales.</li><li>eSports momentum.</li><li>Shares&nbsp;<font color='green'>+1.8%</font>&nbsp;premarket to $228.50.</li><li><a href=\"https://twitter.com/JayIKyle/status/954185882323574785\" target=\"_blank\">Source</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3323795\" data-linked=\"BofA hikes Nvidia price target, estimates\" data-tweet=\"$NVDA - BofA hikes Nvidia price target, estimates https://seekingalpha.com/news/3323795-bofa-hikes-nvidia-price-target-estimates?source=tweet\" data-url=\"https://seekingalpha.com/news/3323795-bofa-hikes-nvidia-price-target-estimates\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:37 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>31&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323793\" data-ts=\"1516357404\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SQ\" target=\"_blank\">SQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323793-square-jumps-on-bullish-nomura-call\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Square jumps on bullish Nomura call</a></h4><ul><li>Nomura raises Square (NYSE:<a href='https://seekingalpha.com/symbol/SQ' title='Square, Inc.'>SQ</a>) price target from $48 to $64, Street high, predicting 2018 will be another \"phenomenal\" year.</li><li>Says it's now using a valuation methodology like in the \"early days of Amazon and Google.\"</li><li>In 10 years, SQ will likely be a very different company, helped by accelerating share gains from payment peers and relentless disruption of services like payroll and HR.</li><li>Shares&nbsp;<font color='green'>+3.7%</font>&nbsp;to $41.76 premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3323793\" data-linked=\"Square jumps on bullish Nomura call\" data-tweet=\"$SQ - Square jumps on bullish Nomura call https://seekingalpha.com/news/3323793-square-jumps-on-bullish-nomura-call?source=tweet\" data-url=\"https://seekingalpha.com/news/3323793-square-jumps-on-bullish-nomura-call\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":74,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}